{
  "symbol": "RVNC",
  "company_name": "Revance Therapeutics",
  "ir_website": "https://investors.revance.com/overview/default.aspx",
  "structured_data": [
    {
      "section_name": "Press Releases",
      "links": [
        {
          "title": "Revance Announces FDA Approval for DaxibotulinumtoxinA Injection",
          "url": "https://investors.revance.com/investors/Press-Releases/default.aspx",
          "content": "[Skip to main content](#maincontent)\n\n[![Revance Logo](//s202.q4cdn.com/113424049/files/design/logo-revance.png)](/)\n\n  * [COMPANY](https://www.revance.com)\n  * [PRODUCTS AND PIPELINE](https://www.revance.com/products)\n  * [INVESTORS](/)\n\n[INVESTOR RELATIONS](/)[PRESS RELEASES](/investors/Press-Releases)[EVENTS + PRESENTATIONS](/investors/events-and-presentations/events)[FINANCIALS & FILINGS](/investors/financials)[CORPORATE GOVERNANCE](/investors/corporate-governance/governance-documents)\n\n[STOCK INFORMATION](/investors/stock-info)[ANALYST COVERAGE](/investors/analyst-coverage)[INVESTOR FAQS](/investors/investor-faqs)[CONTACT US](/investors/contact-us)\n\n![Investors](//s202.q4cdn.com/113424049/files/design/irmenubanner.png)\n\n  * [CAREERS](https://www.revance.com/careers/)\n  * [IN THE NEWS](https://www.revance.com/news)\n  * [CONTACT US](https://www.revance.com/company/contact-us/)\n\n\n\nUser Menu\n\n  * [LOGIN](https://hcp.revanceready.com/s/login/)\n\n\n\n# Press Releases\n\nIR MENU\n\nSelecting a year value will change the news content\n\nSelect Year:\n\nLoading\n\n✓\n\nThanks for sharing!\n\n[AddToAny](https://www.addtoany.com \"Share Buttons\")\n\n[More…](#addtoany \"Show all\")\n"
        },
        {
          "title": "Revance Therapeutics Announces Q2 2024 Results",
          "url": "https://investors.revance.com/investors/Press-Releases/default.aspx",
          "content": "[Skip to main content](#maincontent)\n\n[![Revance Logo](//s202.q4cdn.com/113424049/files/design/logo-revance.png)](/)\n\n  * [COMPANY](https://www.revance.com)\n  * [PRODUCTS AND PIPELINE](https://www.revance.com/products)\n  * [INVESTORS](/)\n\n[INVESTOR RELATIONS](/)[PRESS RELEASES](/investors/Press-Releases)[EVENTS + PRESENTATIONS](/investors/events-and-presentations/events)[FINANCIALS & FILINGS](/investors/financials)[CORPORATE GOVERNANCE](/investors/corporate-governance/governance-documents)\n\n[STOCK INFORMATION](/investors/stock-info)[ANALYST COVERAGE](/investors/analyst-coverage)[INVESTOR FAQS](/investors/investor-faqs)[CONTACT US](/investors/contact-us)\n\n![Investors](//s202.q4cdn.com/113424049/files/design/irmenubanner.png)\n\n  * [CAREERS](https://www.revance.com/careers/)\n  * [IN THE NEWS](https://www.revance.com/news)\n  * [CONTACT US](https://www.revance.com/company/contact-us/)\n\n\n\nUser Menu\n\n  * [LOGIN](https://hcp.revanceready.com/s/login/)\n\n\n\n# Press Releases\n\nIR MENU\n\nSelecting a year value will change the news content\n\nSelect Year:\n\nAll202420232022202120202019201820172016201520142013\n\nShowing All undefined News\n\nNovember 7, 2024 \n\n[Revance Reports Third Quarter 2024 Financial Results, Provides Corporate Update](/investors/Press-Releases/news-details/2024/Revance-Reports-Third-Quarter-2024-Financial-Results-Provides-Corporate-Update/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2024/Revance-Reports-Third-Quarter-2024-Financial-Results-Provides-Corporate-Update/default.aspx)\n\nAugust 12, 2024 \n\n[Crown Laboratories and Revance Announce Entry Into Merger Agreement](/investors/Press-Releases/news-details/2024/Crown-Laboratories-and-Revance-Announce-Entry-Into-Merger-Agreement/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2024/Crown-Laboratories-and-Revance-Announce-Entry-Into-Merger-Agreement/default.aspx)\n\nAugust 8, 2024 \n\n[Revance Reports Second Quarter 2024 Financial Results, Provides Corporate Update](/investors/Press-Releases/news-details/2024/Revance-Reports-Second-Quarter-2024-Financial-Results-Provides-Corporate-Update/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2024/Revance-Reports-Second-Quarter-2024-Financial-Results-Provides-Corporate-Update/default.aspx)\n\nAugust 1, 2024 \n\n[Revance to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024](/investors/Press-Releases/news-details/2024/Revance-to-Release-Second-Quarter-2024-Financial-Results-on-Thursday-August-8-2024/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2024/Revance-to-Release-Second-Quarter-2024-Financial-Results-on-Thursday-August-8-2024/default.aspx)\n\nJune 14, 2024 \n\n[Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](/investors/Press-Releases/news-details/2024/Revance-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4-8ab665d0a/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2024/Revance-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4-8ab665d0a/default.aspx)\n\nMay 28, 2024 \n\n[Revance to Participate in Upcoming Investor Conferences](/investors/Press-Releases/news-details/2024/Revance-to-Participate-in-Upcoming-Investor-Conferences-2e0dc2a23/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2024/Revance-to-Participate-in-Upcoming-Investor-Conferences-2e0dc2a23/default.aspx)\n\nMay 9, 2024 \n\n[Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update](/investors/Press-Releases/news-details/2024/Revance-Reports-First-Quarter-2024-Financial-Results-Provides-Corporate-Update/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2024/Revance-Reports-First-Quarter-2024-Financial-Results-Provides-Corporate-Update/default.aspx)\n\nMay 9, 2024 \n\n[Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia](/investors/Press-Releases/news-details/2024/Revance-Expands-into-the-U.S.-Therapeutics-Market-with-the-Launch-of-DAXXIFY-for-the-Treatment-of-Cervical-Dystonia/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2024/Revance-Expands-into-the-U.S.-Therapeutics-Market-with-the-Launch-of-DAXXIFY-for-the-Treatment-of-Cervical-Dystonia/default.aspx)\n\nMay 2, 2024 \n\n[Revance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024](/investors/Press-Releases/news-details/2024/Revance-to-Release-First-Quarter-2024-Financial-Results-on-Thursday-May-9-2024/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2024/Revance-to-Release-First-Quarter-2024-Financial-Results-on-Thursday-May-9-2024/default.aspx)\n\nApril 12, 2024 \n\n[Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting](/investors/Press-Releases/news-details/2024/Revance-to-Present-New-DAXXIFY-Data-at-the-American-Academy-of-Neurology-2024-Annual-Meeting/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2024/Revance-to-Present-New-DAXXIFY-Data-at-the-American-Academy-of-Neurology-2024-Annual-Meeting/default.aspx)\n\nMarch 27, 2024 \n\n[Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](/investors/Press-Releases/news-details/2024/Revance-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2024/Revance-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4/default.aspx)\n\nMarch 4, 2024 \n\n[Revance Announces Pricing of $100.0 Million Public Offering of Common Stock](/investors/Press-Releases/news-details/2024/Revance-Announces-Pricing-of-100.0-Million-Public-Offering-of-Common-Stock/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2024/Revance-Announces-Pricing-of-100.0-Million-Public-Offering-of-Common-Stock/default.aspx)\n\nMarch 4, 2024 \n\n[Revance Announces Proposed Public Offering of Common Stock](/investors/Press-Releases/news-details/2024/Revance-Announces-Proposed-Public-Offering-of-Common-Stock/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2024/Revance-Announces-Proposed-Public-Offering-of-Common-Stock/default.aspx)\n\nFebruary 28, 2024 \n\n[Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update](/investors/Press-Releases/news-details/2024/Revance-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-Provides-Corporate-Update/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2024/Revance-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-Provides-Corporate-Update/default.aspx)\n\nFebruary 21, 2024 \n\n[Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024](/investors/Press-Releases/news-details/2024/Revance-to-Release-Fourth-Quarter-and-Full-Year-2023-Financial-Results-on-Wednesday-February-28-2024/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2024/Revance-to-Release-Fourth-Quarter-and-Full-Year-2023-Financial-Results-on-Wednesday-February-28-2024/default.aspx)\n\nFebruary 21, 2024 \n\n[Revance to Participate in Upcoming Investor Conferences](/investors/Press-Releases/news-details/2024/Revance-to-Participate-in-Upcoming-Investor-Conferences/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2024/Revance-to-Participate-in-Upcoming-Investor-Conferences/default.aspx)\n\nFebruary 2, 2024 \n\n[Revance Receives Permanent J-Code for DAXXIFY® and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology®](/investors/Press-Releases/news-details/2024/Revance-Receives-Permanent-J-Code-for-DAXXIFY-and-Announces-Publication-of-DAXXIFY-Pivotal-Study-ASPEN-1-Results-in-Neurology/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2024/Revance-Receives-Permanent-J-Code-for-DAXXIFY-and-Announces-Publication-of-DAXXIFY-Pivotal-Study-ASPEN-1-Results-in-Neurology/default.aspx)\n\nFebruary 1, 2024 \n\n[Revance to Participate in the Guggenheim 6th Annual Biotechnology Conference](/investors/Press-Releases/news-details/2024/Revance-to-Participate-in-the-Guggenheim-6th-Annual-Biotechnology-Conference/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2024/Revance-to-Participate-in-the-Guggenheim-6th-Annual-Biotechnology-Conference/default.aspx)\n\nJanuary 8, 2024 \n\n[Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook](/investors/Press-Releases/news-details/2024/Revance-Provides-Corporate-Update-Preliminary-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Financial-Outlook/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2024/Revance-Provides-Corporate-Update-Preliminary-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Financial-Outlook/default.aspx)\n\nNovember 8, 2023 \n\n[Revance Reports Third Quarter 2023 Financial Results, Provides Corporate Update](/investors/Press-Releases/news-details/2023/Revance-Reports-Third-Quarter-2023-Financial-Results-Provides-Corporate-Update/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2023/Revance-Reports-Third-Quarter-2023-Financial-Results-Provides-Corporate-Update/default.aspx)\n\nNovember 8, 2023 \n\n[Revance Appoints Erica Jordan as Chief Commercial Officer, Aesthetics](/investors/Press-Releases/news-details/2023/Revance-Appoints-Erica-Jordan-as-Chief-Commercial-Officer-Aesthetics/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2023/Revance-Appoints-Erica-Jordan-as-Chief-Commercial-Officer-Aesthetics/default.aspx)\n\nNovember 6, 2023 \n\n[Revance to Participate in Upcoming Investor Conferences](/investors/Press-Releases/news-details/2023/Revance-to-Participate-in-Upcoming-Investor-Conferences/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2023/Revance-to-Participate-in-Upcoming-Investor-Conferences/default.aspx)\n\nNovember 1, 2023 \n\n[Revance to Release Third Quarter 2023 Financial Results on Wednesday, November 8, 2023](/investors/Press-Releases/news-details/2023/Revance-to-Release-Third-Quarter-2023-Financial-Results-on-Wednesday-November-8-2023/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2023/Revance-to-Release-Third-Quarter-2023-Financial-Results-on-Wednesday-November-8-2023/default.aspx)\n\nOctober 26, 2023 \n\n[DAXXIFY® Becomes First Facial Injectable to be Named to TIME’s Best Inventions](/investors/Press-Releases/news-details/2023/DAXXIFY-Becomes-First-Facial-Injectable-to-be-Named-to-TIMEs-Best-Inventions/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2023/DAXXIFY-Becomes-First-Facial-Injectable-to-be-Named-to-TIMEs-Best-Inventions/default.aspx)\n\nSeptember 19, 2023 \n\n[Revance Provides Corporate Update at Investor Day](/investors/Press-Releases/news-details/2023/Revance-Provides-Corporate-Update-at-Investor-Day/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2023/Revance-Provides-Corporate-Update-at-Investor-Day/default.aspx)\n\nAugust 22, 2023 \n\n[Revance to Host Investor Day on September 19, 2023](/investors/Press-Releases/news-details/2023/Revance-to-Host-Investor-Day-on-September-19-2023/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2023/Revance-to-Host-Investor-Day-on-September-19-2023/default.aspx)\n\nAugust 14, 2023 \n\n[U.S. FDA Approves First Therapeutic Indication for Revance’s DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia](/investors/Press-Releases/news-details/2023/U.S.-FDA-Approves-First-Therapeutic-Indication-for-Revances-DAXXIFY-DaxibotulinumtoxinA-lanm-for-Injection-for-the-Treatment-of-Cervical-Dystonia/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2023/U.S.-FDA-Approves-First-Therapeutic-Indication-for-Revances-DAXXIFY-DaxibotulinumtoxinA-lanm-for-Injection-for-the-Treatment-of-Cervical-Dystonia/default.aspx)\n\nAugust 8, 2023 \n\n[Revance Reports Second Quarter 2023 Financial Results, Provides Corporate Update](/investors/Press-Releases/news-details/2023/Revance-Reports-Second-Quarter-2023-Financial-Results-Provides-Corporate-Update/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2023/Revance-Reports-Second-Quarter-2023-Financial-Results-Provides-Corporate-Update/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2023/08/Revance-Reports-Second-Quarter-2023-Financial-Results-Provides-Corporate-Update.pdf)\n\nAugust 1, 2023 \n\n[Revance to Release Second Quarter 2023 Financial Results on Tuesday, August 8, 2023](/investors/Press-Releases/news-details/2023/Revance-to-Release-Second-Quarter-2023-Financial-Results-on-Tuesday-August-8-2023/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2023/Revance-to-Release-Second-Quarter-2023-Financial-Results-on-Tuesday-August-8-2023/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2023/08/Revance-to-Release-Second-Quarter-2023-Financial-Results-on-Tuesday-August-8-2023.pdf)\n\nMay 23, 2023 \n\n[Revance to Participate in Upcoming Investor Conferences](/investors/Press-Releases/news-details/2023/Revance-to-Participate-in-Upcoming-Investor-Conferences-05-23-2023/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2023/Revance-to-Participate-in-Upcoming-Investor-Conferences-05-23-2023/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2023/05/News-Release-05-23-2023-1690222910505220.pdf)\n\nMay 9, 2023 \n\n[Revance Reports First Quarter 2023 Financial Results, Provides Corporate Update](/investors/Press-Releases/news-details/2023/Revance-Reports-First-Quarter-2023-Financial-Results-Provides-Corporate-Update-05-09-2023/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2023/Revance-Reports-First-Quarter-2023-Financial-Results-Provides-Corporate-Update-05-09-2023/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2023/05/News-Release-05-09-2023-1690222910506714.pdf)\n\nMay 2, 2023 \n\n[Revance to Release First Quarter 2023 Financial Results on Tuesday, May 9, 2023](/investors/Press-Releases/news-details/2023/Revance-to-Release-First-Quarter-2023-Financial-Results-on-Tuesday-May-9-2023-05-02-2023/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2023/Revance-to-Release-First-Quarter-2023-Financial-Results-on-Tuesday-May-9-2023-05-02-2023/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2023/05/News-Release-05-02-2023-1690222910506798.pdf)\n\nApril 5, 2023 \n\n[Revance to Participate in the Needham 22nd Annual Healthcare Conference](/investors/Press-Releases/news-details/2023/Revance-to-Participate-in-the-Needham-22nd-Annual-Healthcare-Conference-04-05-2023/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2023/Revance-to-Participate-in-the-Needham-22nd-Annual-Healthcare-Conference-04-05-2023/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2023/04/News-Release-04-05-2023-1690222910506702.pdf)\n\nMarch 30, 2023 \n\n[Revance Publishes its 2022 Environmental, Social, and Governance (ESG) Report](/investors/Press-Releases/news-details/2023/Revance-Publishes-its-2022-Environmental-Social-and-Governance-ESG-Report-03-30-2023/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2023/Revance-Publishes-its-2022-Environmental-Social-and-Governance-ESG-Report-03-30-2023/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2023/03/News-Release-03-30-2023-1690222910506289.pdf)\n\nMarch 7, 2023 \n\n[Revance to Participate in Upcoming Investor Conferences](/investors/Press-Releases/news-details/2023/Revance-to-Participate-in-Upcoming-Investor-Conferences-03-07-2023/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2023/Revance-to-Participate-in-Upcoming-Investor-Conferences-03-07-2023/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2023/03/News-Release-03-07-2023-1690222910506550.pdf)\n\nFebruary 28, 2023 \n\n[Revance Adds Experienced Pharmaceutical Executive to Board of Directors with Appointment of Dr. Vlad Coric, M.D., as Independent Director](/investors/Press-Releases/news-details/2023/Revance-Adds-Experienced-Pharmaceutical-Executive-to-Board-of-Directors-with-Appointment-of-Dr.-Vlad-Coric-M.D.-as-Independent-Director-02-28-2023/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2023/Revance-Adds-Experienced-Pharmaceutical-Executive-to-Board-of-Directors-with-Appointment-of-Dr.-Vlad-Coric-M.D.-as-Independent-Director-02-28-2023/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2023/02/News-Release-02-28-2023-1690222910506586.pdf)\n\nFebruary 28, 2023 \n\n[Revance Reports Fourth Quarter and Full Year 2022 Financial Results, Provides Corporate Update](/investors/Press-Releases/news-details/2023/Revance-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results-Provides-Corporate-Update-02-28-2023/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2023/Revance-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results-Provides-Corporate-Update-02-28-2023/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2023/02/News-Release-02-28-2023-1690222910506559.pdf)\n\nFebruary 27, 2023 \n\n[Revance to Participate in the 43rd Annual Cowen Healthcare Conference](/investors/Press-Releases/news-details/2023/Revance-to-Participate-in-the-43rd-Annual-Cowen-Healthcare-Conference-02-27-2023/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2023/Revance-to-Participate-in-the-43rd-Annual-Cowen-Healthcare-Conference-02-27-2023/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2023/02/News-Release-02-27-2023-1690222910506689.pdf)\n\nFebruary 23, 2023 \n\n[Revance to Present New Data on DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia at the Association of Academic Physiatrists Annual Meeting](/investors/Press-Releases/news-details/2023/Revance-to-Present-New-Data-on-DAXXIFY-DaxibotulinumtoxinA-lanm-for-Injection-for-the-Treatment-of-Cervical-Dystonia-at-the-Association-of-Academic-Physiatrists-Annual-Meeting-02-23-2023/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2023/Revance-to-Present-New-Data-on-DAXXIFY-DaxibotulinumtoxinA-lanm-for-Injection-for-the-Treatment-of-Cervical-Dystonia-at-the-Association-of-Academic-Physiatrists-Annual-Meeting-02-23-2023/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2023/02/News-Release-02-23-2023-1690222910507167.pdf)\n\nFebruary 21, 2023 \n\n[Revance to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 28, 2023](/investors/Press-Releases/news-details/2023/Revance-to-Release-Fourth-Quarter-and-Full-Year-2022-Financial-Results-on-Tuesday-February-28-2023-02-21-2023/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2023/Revance-to-Release-Fourth-Quarter-and-Full-Year-2022-Financial-Results-on-Tuesday-February-28-2023-02-21-2023/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2023/02/News-Release-02-21-2023-1690222917238565.pdf)\n\nJanuary 9, 2023 \n\n[Revance Provides an Update on DAXXIFY® Commercial Launch and Preliminary Fourth Quarter and Full Year 2022 Financial Results](/investors/Press-Releases/news-details/2023/Revance-Provides-an-Update-on-DAXXIFY-Commercial-Launch-and-Preliminary-Fourth-Quarter-and-Full-Year-2022-Financial-Results-01-09-2023/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2023/Revance-Provides-an-Update-on-DAXXIFY-Commercial-Launch-and-Preliminary-Fourth-Quarter-and-Full-Year-2022-Financial-Results-01-09-2023/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2023/01/News-Release-01-09-2023-1690222917238416.pdf)\n\nJanuary 6, 2023 \n\n[Revance Announces U.S. FDA Acceptance of Supplemental Biologics License Application (sBLA) for DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia](/investors/Press-Releases/news-details/2023/Revance-Announces-U.S.-FDA-Acceptance-of-Supplemental-Biologics-License-Application-sBLA-for-DAXXIFY-DaxibotulinumtoxinA-lanm-for-Injection-for-the-Treatment-of-Cervical-Dystonia-01-06-2023/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2023/Revance-Announces-U.S.-FDA-Acceptance-of-Supplemental-Biologics-License-Application-sBLA-for-DAXXIFY-DaxibotulinumtoxinA-lanm-for-Injection-for-the-Treatment-of-Cervical-Dystonia-01-06-2023/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2023/01/News-Release-01-06-2023-1690222917238968.pdf)\n\nNovember 22, 2022 \n\n[Revance to Participate in the 34th Annual Piper Sandler Healthcare Conference](/investors/Press-Releases/news-details/2022/Revance-to-Participate-in-the-34th-Annual-Piper-Sandler-Healthcare-Conference-11-22-2022/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2022/Revance-to-Participate-in-the-34th-Annual-Piper-Sandler-Healthcare-Conference-11-22-2022/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2022/11/News-Release-11-22-2022-1690222917238570.pdf)\n\nNovember 9, 2022 \n\n[Revance to Participate in the Stifel 2022 Healthcare Conference](/investors/Press-Releases/news-details/2022/Revance-to-Participate-in-the-Stifel-2022-Healthcare-Conference-11-09-2022/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2022/Revance-to-Participate-in-the-Stifel-2022-Healthcare-Conference-11-09-2022/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2022/11/News-Release-11-09-2022-1690222917238809.pdf)\n\nNovember 8, 2022 \n\n[Revance Reports Third Quarter 2022 Financial Results, Provides Corporate Update](/investors/Press-Releases/news-details/2022/Revance-Reports-Third-Quarter-2022-Financial-Results-Provides-Corporate-Update-11-08-2022/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2022/Revance-Reports-Third-Quarter-2022-Financial-Results-Provides-Corporate-Update-11-08-2022/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2022/11/News-Release-11-08-2022-1690222917239423.pdf)\n\nNovember 4, 2022 \n\n[Revance Announces Two Publications in The Aesthetic Surgery Journal That Advance Glabellar Line Injection Technique and Assessment](/investors/Press-Releases/news-details/2022/Revance-Announces-Two-Publications-in-The-Aesthetic-Surgery-Journal-That-Advance-Glabellar-Line-Injection-Technique-and-Assessment-11-04-2022/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2022/Revance-Announces-Two-Publications-in-The-Aesthetic-Surgery-Journal-That-Advance-Glabellar-Line-Injection-Technique-and-Assessment-11-04-2022/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2022/11/News-Release-11-04-2022-1690222917239579.pdf)\n\nNovember 1, 2022 \n\n[Revance to Release Third Quarter 2022 Financial Results on Tuesday, November 8, 2022](/investors/Press-Releases/news-details/2022/Revance-to-Release-Third-Quarter-2022-Financial-Results-on-Tuesday-November-8-2022-11-01-2022/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2022/Revance-to-Release-Third-Quarter-2022-Financial-Results-on-Tuesday-November-8-2022-11-01-2022/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2022/11/News-Release-11-01-2022-1690222917239334.pdf)\n\nOctober 20, 2022 \n\n[Revance Submits Supplemental Biologics License Application (sBLA) for DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia](/investors/Press-Releases/news-details/2022/Revance-Submits-Supplemental-Biologics-License-Application-sBLA-for-DAXXIFY-DaxibotulinumtoxinA-lanm-for-Injection-for-the-Treatment-of-Cervical-Dystonia-10-20-2022/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2022/Revance-Submits-Supplemental-Biologics-License-Application-sBLA-for-DAXXIFY-DaxibotulinumtoxinA-lanm-for-Injection-for-the-Treatment-of-Cervical-Dystonia-10-20-2022/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2022/10/News-Release-10-20-2022-1690222917239830.pdf)\n\nOctober 17, 2022 \n\n[Revance Appoints David A. Hollander, M.D., M.B.A. as Chief Medical Officer](/investors/Press-Releases/news-details/2022/Revance-Appoints-David-A.-Hollander-M.D.-M.B.A.-as-Chief-Medical-Officer-10-17-2022/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2022/Revance-Appoints-David-A.-Hollander-M.D.-M.B.A.-as-Chief-Medical-Officer-10-17-2022/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2022/10/News-Release-10-17-2022-1690222917239731.pdf)\n\nOctober 10, 2022 \n\n[Revance to Present Clinical Data on the Efficacy and Safety Profile of DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting](/investors/Press-Releases/news-details/2022/Revance-to-Present-Clinical-Data-on-the-Efficacy-and-Safety-Profile-of-DAXXIFY-DaxibotulinumtoxinA-lanm-for-Injection-at-the-2022-American-Society-for-Dermatologic-Surgery-ASDS-Annual-Meeting-10-10-2022/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2022/Revance-to-Present-Clinical-Data-on-the-Efficacy-and-Safety-Profile-of-DAXXIFY-DaxibotulinumtoxinA-lanm-for-Injection-at-the-2022-American-Society-for-Dermatologic-Surgery-ASDS-Annual-Meeting-10-10-2022/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2022/10/News-Release-10-10-2022-1690222923918832.pdf)\n\nSeptember 21, 2022 \n\n[Revance to Participate in the Guggenheim Nantucket Therapeutics Conference](/investors/Press-Releases/news-details/2022/Revance-to-Participate-in-the-Guggenheim-Nantucket-Therapeutics-Conference-09-21-2022/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2022/Revance-to-Participate-in-the-Guggenheim-Nantucket-Therapeutics-Conference-09-21-2022/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2022/09/News-Release-09-21-2022-1690222923918513.pdf)\n\nSeptember 19, 2022 \n\n[Revance Announces Two Publications Highlighting the Efficacy and Safety Profile of DAXXIFY™ (DaxibotulinumtoxinA-lanm) For Injection in the Aesthetic Surgery Journal](/investors/Press-Releases/news-details/2022/Revance-Announces-Two-Publications-Highlighting-the-Efficacy-and-Safety-Profile-of-DAXXIFY-DaxibotulinumtoxinA-lanm-For-Injection-in-the-Aesthetic-Surgery-Journal-09-19-2022/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2022/Revance-Announces-Two-Publications-Highlighting-the-Efficacy-and-Safety-Profile-of-DAXXIFY-DaxibotulinumtoxinA-lanm-For-Injection-in-the-Aesthetic-Surgery-Journal-09-19-2022/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2022/09/News-Release-09-19-2022-169022292391876.pdf)\n\nSeptember 15, 2022 \n\n[Revance to Present Data from Phase 2 JUNIPER Clinical Trial Evaluating DAXXIFY™ (DaxibotulinumtoxinA-lanm) Injection for the Treatment of Upper Limb Spasticity at the International Congress of Parkinson and Movement Disorder Society (MDS)](/investors/Press-Releases/news-details/2022/Revance-to-Present-Data-from-Phase-2-JUNIPER-Clinical-Trial-Evaluating-DAXXIFY-DaxibotulinumtoxinA-lanm-Injection-for-the-Treatment-of-Upper-Limb-Spasticity-at-the-International-Congress-of-Parkinson-and-Movement-Disorder-Socie-09-15-2022/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2022/Revance-to-Present-Data-from-Phase-2-JUNIPER-Clinical-Trial-Evaluating-DAXXIFY-DaxibotulinumtoxinA-lanm-Injection-for-the-Treatment-of-Upper-Limb-Spasticity-at-the-International-Congress-of-Parkinson-and-Movement-Disorder-Socie-09-15-2022/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2022/09/News-Release-09-15-2022-1690222923918332.pdf)\n\nSeptember 15, 2022 \n\n[Revance Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares](/investors/Press-Releases/news-details/2022/Revance-Announces-Closing-of-Public-Offering-and-Full-Exercise-of-the-Underwriters-Option-to-Purchase-Additional-Shares-09-15-2022/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2022/Revance-Announces-Closing-of-Public-Offering-and-Full-Exercise-of-the-Underwriters-Option-to-Purchase-Additional-Shares-09-15-2022/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2022/09/News-Release-09-15-2022-1690222923919471.pdf)\n\nSeptember 12, 2022 \n\n[Revance Announces Pricing of $200.0 Million Upsized Public Offering of Common Stock](/investors/Press-Releases/news-details/2022/Revance-Announces-Pricing-of-200.0-Million-Upsized-Public-Offering-of-Common-Stock-09-12-2022/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2022/Revance-Announces-Pricing-of-200.0-Million-Upsized-Public-Offering-of-Common-Stock-09-12-2022/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2022/09/News-Release-09-12-2022-16902229239193.pdf)\n\nSeptember 12, 2022 \n\n[Revance Announces Proposed Public Offering of Common Stock](/investors/Press-Releases/news-details/2022/Revance-Announces-Proposed-Public-Offering-of-Common-Stock-09-12-2022/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2022/Revance-Announces-Proposed-Public-Offering-of-Common-Stock-09-12-2022/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2022/09/News-Release-09-12-2022-1690222923919640.pdf)\n\nSeptember 8, 2022 \n\n[Revance Announces FDA Approval of DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection, the First and Only Peptide-Formulated Neuromodulator With Long-Lasting Results](/investors/Press-Releases/news-details/2022/Revance-Announces-FDA-Approval-of-DAXXIFY-DaxibotulinumtoxinA-lanm-for-Injection-the-First-and-Only-Peptide-Formulated-Neuromodulator-With-Long-Lasting-Results-09-08-2022/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2022/Revance-Announces-FDA-Approval-of-DAXXIFY-DaxibotulinumtoxinA-lanm-for-Injection-the-First-and-Only-Peptide-Formulated-Neuromodulator-With-Long-Lasting-Results-09-08-2022/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2022/09/News-Release-09-08-2022-1690222923919448.pdf)\n\nAugust 9, 2022 \n\n[Revance Reports Second Quarter 2022 Financial Results, Provides Corporate Update](/investors/Press-Releases/news-details/2022/Revance-Reports-Second-Quarter-2022-Financial-Results-Provides-Corporate-Update-08-09-2022/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2022/Revance-Reports-Second-Quarter-2022-Financial-Results-Provides-Corporate-Update-08-09-2022/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2022/08/News-Release-08-09-2022-1690222923919896.pdf)\n\nAugust 2, 2022 \n\n[Revance to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022](/investors/Press-Releases/news-details/2022/Revance-to-Release-Second-Quarter-2022-Financial-Results-on-Tuesday-August-9-2022-08-02-2022/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2022/Revance-to-Release-Second-Quarter-2022-Financial-Results-on-Tuesday-August-9-2022-08-02-2022/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2022/08/News-Release-08-02-2022-1690222923920171.pdf)\n\nJuly 27, 2022 \n\n[Revance To Present Clinical Data on DaxibotulinumtoxinA for Injection at the 2022 TOXINS International Conference](/investors/Press-Releases/news-details/2022/Revance-To-Present-Clinical-Data-on-DaxibotulinumtoxinA-for-Injection-at-the-2022-TOXINS-International-Conference-07-27-2022/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2022/Revance-To-Present-Clinical-Data-on-DaxibotulinumtoxinA-for-Injection-at-the-2022-TOXINS-International-Conference-07-27-2022/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2022/07/News-Release-07-27-2022-1690222930538728.pdf)\n\nMay 23, 2022 \n\n[Revance to Participate in the William Blair 42nd Annual Growth Stock Conference](/investors/Press-Releases/news-details/2022/Revance-to-Participate-in-the-William-Blair-42nd-Annual-Growth-Stock-Conference-05-23-2022/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2022/Revance-to-Participate-in-the-William-Blair-42nd-Annual-Growth-Stock-Conference-05-23-2022/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2022/05/News-Release-05-23-2022-1690222930538933.pdf)\n\nMay 10, 2022 \n\n[Revance Reports First Quarter 2022 Financial Results, Provides Corporate Update](/investors/Press-Releases/news-details/2022/Revance-Reports-First-Quarter-2022-Financial-Results-Provides-Corporate-Update-05-10-2022/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2022/Revance-Reports-First-Quarter-2022-Financial-Results-Provides-Corporate-Update-05-10-2022/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2022/05/News-Release-05-10-2022-169022293053838.pdf)\n\nMay 3, 2022 \n\n[Revance to Release First Quarter Financial Results on Tuesday, May 10, 2022](/investors/Press-Releases/news-details/2022/Revance-to-Release-First-Quarter-Financial-Results-on-Tuesday-May-10-2022-05-03-2022/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2022/Revance-to-Release-First-Quarter-Financial-Results-on-Tuesday-May-10-2022-05-03-2022/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2022/05/News-Release-05-03-2022-1690222930538933.pdf)\n\nApril 21, 2022 \n\n[Revance Receives FDA Acceptance of BLA Resubmission for DaxibotulinumtoxinA for Injection for Glabellar Lines](/investors/Press-Releases/news-details/2022/Revance-Receives-FDA-Acceptance-of-BLA-Resubmission-for-DaxibotulinumtoxinA-for-Injection-for-Glabellar-Lines-04-21-2022/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2022/Revance-Receives-FDA-Acceptance-of-BLA-Resubmission-for-DaxibotulinumtoxinA-for-Injection-for-Glabellar-Lines-04-21-2022/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2022/04/News-Release-04-21-2022-1690222930538381.pdf)\n\nMarch 28, 2022 \n\n[Revance to Present New Clinical Data on DaxibotulinumtoxinA for Injection from the ASPEN Phase 3 Program at the 2022 American Academy of Neurology Annual Meeting](/investors/Press-Releases/news-details/2022/Revance-to-Present-New-Clinical-Data-on-DaxibotulinumtoxinA-for-Injection-from-the-ASPEN-Phase-3-Program-at-the-2022-American-Academy-of-Neurology-Annual-Meeting-03-28-2022/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2022/Revance-to-Present-New-Clinical-Data-on-DaxibotulinumtoxinA-for-Injection-from-the-ASPEN-Phase-3-Program-at-the-2022-American-Academy-of-Neurology-Annual-Meeting-03-28-2022/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2022/03/News-Release-03-28-2022-169022293053811.pdf)\n\nMarch 21, 2022 \n\n[Revance Closes on $300 Million Note Purchase Agreement with Athyrium Capital Management](/investors/Press-Releases/news-details/2022/Revance-Closes-on-300-Million-Note-Purchase-Agreement-with-Athyrium-Capital-Management-03-21-2022/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2022/Revance-Closes-on-300-Million-Note-Purchase-Agreement-with-Athyrium-Capital-Management-03-21-2022/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2022/03/News-Release-03-21-2022-1690222930539445.pdf)\n\nMarch 8, 2022 \n\n[Revance Resubmits Biologics License Application for DaxibotulinumtoxinA for Injection for Glabellar Lines to the FDA](/investors/Press-Releases/news-details/2022/Revance-Resubmits-Biologics-License-Application-for-DaxibotulinumtoxinA-for-Injection-for-Glabellar-Lines-to-the-FDA-03-08-2022/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2022/Revance-Resubmits-Biologics-License-Application-for-DaxibotulinumtoxinA-for-Injection-for-Glabellar-Lines-to-the-FDA-03-08-2022/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2022/03/News-Release-03-08-2022-1690222930539655.pdf)\n\nMarch 2, 2022 \n\n[Revance to Participate in the Cowen 42nd Annual Health Care Conference](/investors/Press-Releases/news-details/2022/Revance-to-Participate-in-the-Cowen-42nd-Annual-Health-Care-Conference-03-02-2022/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2022/Revance-to-Participate-in-the-Cowen-42nd-Annual-Health-Care-Conference-03-02-2022/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2022/03/News-Release-03-02-2022-1690222930539245.pdf)\n\nFebruary 28, 2022 \n\n[Revance Reports Fourth Quarter and Full Year 2021 Financial Results, Provides Corporate Update](/investors/Press-Releases/news-details/2022/Revance-Reports-Fourth-Quarter-and-Full-Year-2021-Financial-Results-Provides-Corporate-Update-02-28-2022/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2022/Revance-Reports-Fourth-Quarter-and-Full-Year-2021-Financial-Results-Provides-Corporate-Update-02-28-2022/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2022/02/News-Release-02-28-2022-1690222930539437.pdf)\n\nFebruary 22, 2022 \n\n[Revance to Release Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022](/investors/Press-Releases/news-details/2022/Revance-to-Release-Fourth-Quarter-and-Full-Year-2021-Financial-Results-on-Monday-February-28-2022-02-22-2022/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2022/Revance-to-Release-Fourth-Quarter-and-Full-Year-2021-Financial-Results-on-Monday-February-28-2022-02-22-2022/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2022/02/News-Release-02-22-2022-1690222937095936.pdf)\n\nJanuary 18, 2022 \n\n[Revance Receives Clarity on Path to Resubmission of the BLA for DaxibotulinumtoxinA for Injection Following Type A Meeting with FDA](/investors/Press-Releases/news-details/2022/Revance-Receives-Clarity-on-Path-to-Resubmission-of-the-BLA-for-DaxibotulinumtoxinA-for-Injection-Following-Type-A-Meeting-with-FDA-01-18-2022/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2022/Revance-Receives-Clarity-on-Path-to-Resubmission-of-the-BLA-for-DaxibotulinumtoxinA-for-Injection-Following-Type-A-Meeting-with-FDA-01-18-2022/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2022/01/News-Release-01-18-2022-169022293709647.pdf)\n\nJanuary 7, 2022 \n\n[Revance Provides Preliminary Fourth Quarter and Full Year 2021 Financial Results and a Corporate Update](/investors/Press-Releases/news-details/2022/Revance-Provides-Preliminary-Fourth-Quarter-and-Full-Year-2021-Financial-Results-and-a-Corporate-Update-01-07-2022/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2022/Revance-Provides-Preliminary-Fourth-Quarter-and-Full-Year-2021-Financial-Results-and-a-Corporate-Update-01-07-2022/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2022/01/News-Release-01-07-2022-169022293709623.pdf)\n\nNovember 19, 2021 \n\n[Revance to Present Clinical Data on DaxibotulinumtoxinA for Injection and Hyaluronic Acid Filler Injection Technique at the 2021 American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting](/investors/Press-Releases/news-details/2021/Revance-to-Present-Clinical-Data-on-DaxibotulinumtoxinA-for-Injection-and-Hyaluronic-Acid-Filler-Injection-Technique-at-the-2021-American-Society-for-Dermatologic-Surgery-ASDS-Virtual-Annual-Meeting-11-19-2021/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2021/Revance-to-Present-Clinical-Data-on-DaxibotulinumtoxinA-for-Injection-and-Hyaluronic-Acid-Filler-Injection-Technique-at-the-2021-American-Society-for-Dermatologic-Surgery-ASDS-Virtual-Annual-Meeting-11-19-2021/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2021/11/News-Release-11-19-2021-1690222937096494.pdf)\n\nNovember 18, 2021 \n\n[Revance to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference](/investors/Press-Releases/news-details/2021/Revance-to-Participate-in-the-Piper-Sandler-33rd-Annual-Virtual-Healthcare-Conference-11-18-2021/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2021/Revance-to-Participate-in-the-Piper-Sandler-33rd-Annual-Virtual-Healthcare-Conference-11-18-2021/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2021/11/News-Release-11-18-2021-1690222937096572.pdf)\n\nNovember 10, 2021 \n\n[Revance to Participate in the Stifel 2021 Virtual Healthcare Conference](/investors/Press-Releases/news-details/2021/Revance-to-Participate-in-the-Stifel-2021-Virtual-Healthcare-Conference-11-10-2021/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2021/Revance-to-Participate-in-the-Stifel-2021-Virtual-Healthcare-Conference-11-10-2021/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2021/11/News-Release-11-10-2021-1690222937096334.pdf)\n\nNovember 9, 2021 \n\n[Revance Reports Third Quarter 2021 Financial Results, Provides Corporate Update](/investors/Press-Releases/news-details/2021/Revance-Reports-Third-Quarter-2021-Financial-Results-Provides-Corporate-Update-11-09-2021/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2021/Revance-Reports-Third-Quarter-2021-Financial-Results-Provides-Corporate-Update-11-09-2021/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2021/11/News-Release-11-09-2021-1690222937096125.pdf)\n\nNovember 2, 2021 \n\n[Revance to Release Third Quarter 2021 Financial Results on Tuesday, November 9, 2021](/investors/Press-Releases/news-details/2021/Revance-to-Release-Third-Quarter-2021-Financial-Results-on-Tuesday-November-9-2021-11-02-2021/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2021/Revance-to-Release-Third-Quarter-2021-Financial-Results-on-Tuesday-November-9-2021-11-02-2021/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2021/11/News-Release-11-02-2021-1690222937096352.pdf)\n\nOctober 15, 2021 \n\n[Revance Provides Regulatory Update on DaxibotulinumtoxinA for Injection for the Treatment of Moderate to Severe Glabellar (Frown) Lines](/investors/Press-Releases/news-details/2021/Revance-Provides-Regulatory-Update-on-DaxibotulinumtoxinA-for-Injection-for-the-Treatment-of-Moderate-to-Severe-Glabellar-Frown-Lines-10-15-2021/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2021/Revance-Provides-Regulatory-Update-on-DaxibotulinumtoxinA-for-Injection-for-the-Treatment-of-Moderate-to-Severe-Glabellar-Frown-Lines-10-15-2021/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2021/10/News-Release-10-15-2021-1690222937096856.pdf)\n\nOctober 12, 2021 \n\n[Revance Continues to Anticipate FDA Approval of DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines in 2021](/investors/Press-Releases/news-details/2021/Revance-Continues-to-Anticipate-FDA-Approval-of-DaxibotulinumtoxinA-for-Injection-for-the-Treatment-of-Glabellar-Lines-in-2021-10-12-2021/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2021/Revance-Continues-to-Anticipate-FDA-Approval-of-DaxibotulinumtoxinA-for-Injection-for-the-Treatment-of-Glabellar-Lines-in-2021-10-12-2021/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2021/10/News-Release-10-12-2021-1690222937096419.pdf)\n\nOctober 11, 2021 \n\n[Revance Announces the Launch of OPUL™, the First-of-its-Kind Relational Commerce Platform for Aesthetic Practices](/investors/Press-Releases/news-details/2021/Revance-Announces-the-Launch-of-OPUL-the-First-of-its-Kind-Relational-Commerce-Platform-for-Aesthetic-Practices-10-11-2021/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2021/Revance-Announces-the-Launch-of-OPUL-the-First-of-its-Kind-Relational-Commerce-Platform-for-Aesthetic-Practices-10-11-2021/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2021/10/News-Release-10-11-2021-1690222943652624.pdf)\n\nSeptember 16, 2021 \n\n[Revance to Showcase Data from Phase 3 ASPEN-1 Clinical Trial Evaluating Efficacy, Duration of Effect and Safety of DaxibotulinumtoxinA for Injection for Cervical Dystonia at International Parkinson and Movement Disorder Society Virtual Congress 2021](/investors/Press-Releases/news-details/2021/Revance-to-Showcase-Data-from-Phase-3-ASPEN-1-Clinical-Trial-Evaluating-Efficacy-Duration-of-Effect-and-Safety-of-DaxibotulinumtoxinA-for-Injection-for-Cervical-Dystonia-at-International-Parkinson-and-Movement-Disorder-Society-Vir-09-16-2021/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2021/Revance-to-Showcase-Data-from-Phase-3-ASPEN-1-Clinical-Trial-Evaluating-Efficacy-Duration-of-Effect-and-Safety-of-DaxibotulinumtoxinA-for-Injection-for-Cervical-Dystonia-at-International-Parkinson-and-Movement-Disorder-Society-Vir-09-16-2021/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2021/09/News-Release-09-16-2021-1690222943652457.pdf)\n\nSeptember 10, 2021 \n\n[Revance Presents Data on the RHA® Collection of Dermal Fillers at the 2021 Virtual Skin of Color Update Meeting](/investors/Press-Releases/news-details/2021/Revance-Presents-Data-on-the-RHA-Collection-of-Dermal-Fillers-at-the-2021-Virtual-Skin-of-Color-Update-Meeting-09-10-2021/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2021/Revance-Presents-Data-on-the-RHA-Collection-of-Dermal-Fillers-at-the-2021-Virtual-Skin-of-Color-Update-Meeting-09-10-2021/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2021/09/News-Release-09-10-2021-169022294365228.pdf)\n\nSeptember 2, 2021 \n\n[Revance to Participate in the Wells Fargo Securities Healthcare Conference](/investors/Press-Releases/news-details/2021/Revance-to-Participate-in-the-Wells-Fargo-Securities-Healthcare-Conference-09-02-2021/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2021/Revance-to-Participate-in-the-Wells-Fargo-Securities-Healthcare-Conference-09-02-2021/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2021/09/News-Release-09-02-2021-1690222943652969.pdf)\n\nSeptember 1, 2021 \n\n[Revance Announces Publication of Results on Static Glabellar Lines With Repeated Treatment of DaxibotulinumtoxinA for Injection From the SAKURA Clinical Program in Dermatologic Surgery](/investors/Press-Releases/news-details/2021/Revance-Announces-Publication-of-Results-on-Static-Glabellar-Lines-With-Repeated-Treatment-of-DaxibotulinumtoxinA-for-Injection-From-the-SAKURA-Clinical-Program-in-Dermatologic-Surgery-09-01-2021/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2021/Revance-Announces-Publication-of-Results-on-Static-Glabellar-Lines-With-Repeated-Treatment-of-DaxibotulinumtoxinA-for-Injection-From-the-SAKURA-Clinical-Program-in-Dermatologic-Surgery-09-01-2021/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2021/09/News-Release-09-01-2021-1690222943653195.pdf)\n\nAugust 5, 2021 \n\n[Revance Reports Second Quarter 2021 Financial Results, Provides Corporate Update](/investors/Press-Releases/news-details/2021/Revance-Reports-Second-Quarter-2021-Financial-Results-Provides-Corporate-Update-08-05-2021/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2021/Revance-Reports-Second-Quarter-2021-Financial-Results-Provides-Corporate-Update-08-05-2021/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2021/08/News-Release-08-05-2021-1690222943653535.pdf)\n\nJuly 29, 2021 \n\n[Revance to Release Second Quarter 2021 Financial Results on Thursday, August 5, 2021](/investors/Press-Releases/news-details/2021/Revance-to-Release-Second-Quarter-2021-Financial-Results-on-Thursday-August-5-2021-07-29-2021/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2021/Revance-to-Release-Second-Quarter-2021-Financial-Results-on-Thursday-August-5-2021-07-29-2021/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2021/07/News-Release-07-29-2021-1690222943653979.pdf)\n\nMay 26, 2021 \n\n[Revance to Participate in Upcoming Virtual Healthcare Conferences](/investors/Press-Releases/news-details/2021/Revance-to-Participate-in-Upcoming-Virtual-Healthcare-Conferences-05-26-2021/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2021/Revance-to-Participate-in-Upcoming-Virtual-Healthcare-Conferences-05-26-2021/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2021/05/News-Release-05-26-2021-1690222943653676.pdf)\n\nMay 26, 2021 \n\n[Revance Provides Update on DaxibotulinumtoxinA for Injection Pre-Approval Inspection](/investors/Press-Releases/news-details/2021/Revance-Provides-Update-on-DaxibotulinumtoxinA-for-Injection-Pre-Approval-Inspection-05-26-2021/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2021/Revance-Provides-Update-on-DaxibotulinumtoxinA-for-Injection-Pre-Approval-Inspection-05-26-2021/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2021/05/News-Release-05-26-2021-1690222943653675.pdf)\n\nMay 10, 2021 \n\n[Revance Reports First Quarter 2021 Financial Results, Provides Corporate Update](/investors/Press-Releases/news-details/2021/Revance-Reports-First-Quarter-2021-Financial-Results-Provides-Corporate-Update-05-10-2021/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2021/Revance-Reports-First-Quarter-2021-Financial-Results-Provides-Corporate-Update-05-10-2021/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2021/05/News-Release-05-10-2021-1690222943653867.pdf)\n\nMay 3, 2021 \n\n[Revance to Release First Quarter 2021 Financial Results on Monday, May 10, 2021](/investors/Press-Releases/news-details/2021/Revance-to-Release-First-Quarter-2021-Financial-Results-on-Monday-May-10-2021-05-03-2021/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2021/Revance-to-Release-First-Quarter-2021-Financial-Results-on-Monday-May-10-2021-05-03-2021/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2021/05/News-Release-05-03-2021-1690222950318937.pdf)\n\nApril 27, 2021 \n\n[Revance to Showcase Clinical Findings at The Aesthetic Meeting 2021 that Supports DaxibotulinumtoxinA’s 24-Week Long Duration Profile Across Multiple Female Age Cohorts](/investors/Press-Releases/news-details/2021/Revance-to-Showcase-Clinical-Findings-at-The-Aesthetic-Meeting-2021-that-Supports-DaxibotulinumtoxinAs-24-Week-Long-Duration-Profile-Across-Multiple-Female-Age-Cohorts-04-27-2021/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2021/Revance-to-Showcase-Clinical-Findings-at-The-Aesthetic-Meeting-2021-that-Supports-DaxibotulinumtoxinAs-24-Week-Long-Duration-Profile-Across-Multiple-Female-Age-Cohorts-04-27-2021/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2021/04/News-Release-04-27-2021-1690222950318659.pdf)\n\nApril 27, 2021 \n\n[Revance Announces First Patient Enrolled for DaxibotulinumtoxinA in Glabellar Lines and Cervical Dystonia in China by Fosun Pharma](/investors/Press-Releases/news-details/2021/Revance-Announces-First-Patient-Enrolled-for-DaxibotulinumtoxinA-in-Glabellar-Lines-and-Cervical-Dystonia-in-China-by-Fosun-Pharma-04-27-2021/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2021/Revance-Announces-First-Patient-Enrolled-for-DaxibotulinumtoxinA-in-Glabellar-Lines-and-Cervical-Dystonia-in-China-by-Fosun-Pharma-04-27-2021/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2021/04/News-Release-04-27-2021-1690222950318970.pdf)\n\nApril 23, 2021 \n\n[Revance to Present Data on DaxibotulinumtoxinA for Injection and Hyaluronic Acid Fillers at American Academy of Dermatology VMX Meeting 2021](/investors/Press-Releases/news-details/2021/Revance-to-Present-Data-on-DaxibotulinumtoxinA-for-Injection-and-Hyaluronic-Acid-Fillers-at-American-Academy-of-Dermatology-VMX-Meeting-2021-04-23-2021/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2021/Revance-to-Present-Data-on-DaxibotulinumtoxinA-for-Injection-and-Hyaluronic-Acid-Fillers-at-American-Academy-of-Dermatology-VMX-Meeting-2021-04-23-2021/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2021/04/News-Release-04-23-2021-1690222950318735.pdf)\n\nApril 6, 2021 \n\n[Revance to Participate in the 20th Annual Needham Virtual Healthcare Conference](/investors/Press-Releases/news-details/2021/Revance-to-Participate-in-the-20th-Annual-Needham-Virtual-Healthcare-Conference-04-06-2021/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2021/Revance-to-Participate-in-the-20th-Annual-Needham-Virtual-Healthcare-Conference-04-06-2021/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2021/04/News-Release-04-06-2021-1690222950318651.pdf)\n\nApril 1, 2021 \n\n[Revance to Showcase Phase 3 Results Evaluating DaxibotulinumtoxinA for Injection for the Treatment of Cervical Dystonia at the American Academy of Neurology Annual 2021 Virtual Meeting](/investors/Press-Releases/news-details/2021/Revance-to-Showcase-Phase-3-Results-Evaluating-DaxibotulinumtoxinA-for-Injection-for-the-Treatment-of-Cervical-Dystonia-at-the-American-Academy-of-Neurology-Annual-2021-Virtual-Meeting-04-01-2021/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2021/Revance-to-Showcase-Phase-3-Results-Evaluating-DaxibotulinumtoxinA-for-Injection-for-the-Treatment-of-Cervical-Dystonia-at-the-American-Academy-of-Neurology-Annual-2021-Virtual-Meeting-04-01-2021/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2021/04/News-Release-04-01-2021-169022295031820.pdf)\n\nMarch 22, 2021 \n\n[Fortune Names Revance to the Top 10 Best Workplaces in Biopharma in 2021](/investors/Press-Releases/news-details/2021/Fortune-Names-Revance-to-the-Top-10-Best-Workplaces-in-Biopharma-in-2021-03-22-2021/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2021/Fortune-Names-Revance-to-the-Top-10-Best-Workplaces-in-Biopharma-in-2021-03-22-2021/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2021/03/News-Release-03-22-2021-1690222950318933.pdf)\n\nFebruary 24, 2021 \n\n[Revance to Participate in Upcoming Virtual Healthcare Conferences](/investors/Press-Releases/news-details/2021/Revance-to-Participate-in-Upcoming-Virtual-Healthcare-Conferences-02-24-2021/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2021/Revance-to-Participate-in-Upcoming-Virtual-Healthcare-Conferences-02-24-2021/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2021/02/News-Release-02-24-2021-1690222950318228.pdf)\n\nFebruary 23, 2021 \n\n[Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](/investors/Press-Releases/news-details/2021/Revance-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4-02-23-2021/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2021/Revance-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4-02-23-2021/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2021/02/News-Release-02-23-2021-1690222950318819.pdf)\n\nFebruary 22, 2021 \n\n[Revance Announces Positive Topline Phase 2 Data Supporting Advancement of DaxibotulinumtoxinA for Injection for the Treatment of Upper Limb Spasticity](/investors/Press-Releases/news-details/2021/Revance-Announces-Positive-Topline-Phase-2-Data-Supporting-Advancement-of-DaxibotulinumtoxinA-for-Injection-for-the-Treatment-of-Upper-Limb-Spasticity-02-22-2021/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2021/Revance-Announces-Positive-Topline-Phase-2-Data-Supporting-Advancement-of-DaxibotulinumtoxinA-for-Injection-for-the-Treatment-of-Upper-Limb-Spasticity-02-22-2021/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2021/02/News-Release-02-22-2021-1690222956868396.pdf)\n\nFebruary 22, 2021 \n\n[Revance Appoints Biotech and Pharmaceutical Executive, Olivia C. Ware, and Fintech and Payments Thought Leader and Entrepreneur, Carey O’Connor Kolaja, to its Board of Directors](/investors/Press-Releases/news-details/2021/Revance-Appoints-Biotech-and-Pharmaceutical-Executive-Olivia-C.-Ware-and-Fintech-and-Payments-Thought-Leader-and-Entrepreneur-Carey-OConnor-Kolaja-to-its-Board-of-Directors-02-22-2021/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2021/Revance-Appoints-Biotech-and-Pharmaceutical-Executive-Olivia-C.-Ware-and-Fintech-and-Payments-Thought-Leader-and-Entrepreneur-Carey-OConnor-Kolaja-to-its-Board-of-Directors-02-22-2021/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2021/02/News-Release-02-22-2021-1690222956868160.pdf)\n\nFebruary 22, 2021 \n\n[Revance Reports Fourth Quarter and Full Year 2020 Financial Results](/investors/Press-Releases/news-details/2021/Revance-Reports-Fourth-Quarter-and-Full-Year-2020-Financial-Results-02-22-2021/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2021/Revance-Reports-Fourth-Quarter-and-Full-Year-2020-Financial-Results-02-22-2021/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2021/02/News-Release-02-22-2021-169022295031850.pdf)\n\nFebruary 12, 2021 \n\n[Revance to Release Fourth Quarter and Full Year 2020 Financial Results on Monday, February 22, 2021](/investors/Press-Releases/news-details/2021/Revance-to-Release-Fourth-Quarter-and-Full-Year-2020-Financial-Results-on-Monday-February-22-2021-02-12-2021/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2021/Revance-to-Release-Fourth-Quarter-and-Full-Year-2020-Financial-Results-on-Monday-February-22-2021-02-12-2021/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2021/02/News-Release-02-12-2021-1690222956868137.pdf)\n\nJanuary 25, 2021 \n\n[Revance to Highlight Aesthetic Clinical Data on DaxibotulinumtoxinA for Injection and Hyaluronic Acid Filler Study Results at Maui Derm for Dermatologists 2021](/investors/Press-Releases/news-details/2021/Revance-to-Highlight-Aesthetic-Clinical-Data-on-DaxibotulinumtoxinA-for-Injection-and-Hyaluronic-Acid-Filler-Study-Results-at-Maui-Derm-for-Dermatologists-2021-01-25-2021/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2021/Revance-to-Highlight-Aesthetic-Clinical-Data-on-DaxibotulinumtoxinA-for-Injection-and-Hyaluronic-Acid-Filler-Study-Results-at-Maui-Derm-for-Dermatologists-2021-01-25-2021/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2021/01/News-Release-01-25-2021-1690222956868411.pdf)\n\nJanuary 22, 2021 \n\n[Revance Issues Inaugural Environmental, Social and Governance (ESG) Report](/investors/Press-Releases/news-details/2021/Revance-Issues-Inaugural-Environmental-Social-and-Governance-ESG-Report-01-22-2021/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2021/Revance-Issues-Inaugural-Environmental-Social-and-Governance-ESG-Report-01-22-2021/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2021/01/News-Release-01-22-2021-1690222956868334.pdf)\n\nJanuary 19, 2021 \n\n[Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](/investors/Press-Releases/news-details/2021/Revance-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4-01-19-2021/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2021/Revance-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4-01-19-2021/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2021/01/News-Release-01-19-2021-1690222956868670.pdf)\n\nJanuary 7, 2021 \n\n[Revance to Participate in the 39th Annual J.P. Morgan Healthcare Conference](/investors/Press-Releases/news-details/2021/Revance-to-Participate-in-the-39th-Annual-J.P.-Morgan-Healthcare-Conference-01-07-2021/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2021/Revance-to-Participate-in-the-39th-Annual-J.P.-Morgan-Healthcare-Conference-01-07-2021/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2021/01/News-Release-01-07-2021-1690222956868994.pdf)\n\nJanuary 7, 2021 \n\n[Revance Provides Corporate Update and Anticipated Milestones for 2021](/investors/Press-Releases/news-details/2021/Revance-Provides-Corporate-Update-and-Anticipated-Milestones-for-2021-01-07-2021/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2021/Revance-Provides-Corporate-Update-and-Anticipated-Milestones-for-2021-01-07-2021/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2021/01/News-Release-01-07-2021-1690222956868306.pdf)\n\nDecember 22, 2020 \n\n[Ajinomoto Bio-Pharma Services and Revance Therapeutics Announce Manufacturing Agreement for Supply of DaxibotulinumtoxinA for Injection](/investors/Press-Releases/news-details/2020/Ajinomoto-Bio-Pharma-Services-and-Revance-Therapeutics-Announce-Manufacturing-Agreement-for-Supply-of-DaxibotulinumtoxinA-for-Injection-12-22-2020/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2020/Ajinomoto-Bio-Pharma-Services-and-Revance-Therapeutics-Announce-Manufacturing-Agreement-for-Supply-of-DaxibotulinumtoxinA-for-Injection-12-22-2020/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2020/12/News-Release-12-22-2020-1690222956868905.pdf)\n\nDecember 21, 2020 \n\n[Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](/investors/Press-Releases/news-details/2020/Revance-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4-12-21-2020/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2020/Revance-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4-12-21-2020/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2020/12/News-Release-12-21-2020-1690222956869989.pdf)\n\nDecember 17, 2020 \n\n[Revance Reports Positive Efficacy and Duration Results from Phase 2 Upper Facial Lines Study](/investors/Press-Releases/news-details/2020/Revance-Reports-Positive-Efficacy-and-Duration-Results-from-Phase-2-Upper-Facial-Lines-Study-12-17-2020/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2020/Revance-Reports-Positive-Efficacy-and-Duration-Results-from-Phase-2-Upper-Facial-Lines-Study-12-17-2020/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2020/12/News-Release-12-17-2020-1690222963825380.pdf)\n\nNovember 25, 2020 \n\n[FDA Defers Approval of DaxibotulinumtoxinA for Injection in Glabellar Lines Due to COVID-19 Related Travel Restrictions Impacting Manufacturing Site Inspection](/investors/Press-Releases/news-details/2020/FDA-Defers-Approval-of-DaxibotulinumtoxinA-for-Injection-in-Glabellar-Lines-Due-to-COVID-19-Related-Travel-Restrictions-Impacting-Manufacturing-Site-Inspection-11-25-2020/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2020/FDA-Defers-Approval-of-DaxibotulinumtoxinA-for-Injection-in-Glabellar-Lines-Due-to-COVID-19-Related-Travel-Restrictions-Impacting-Manufacturing-Site-Inspection-11-25-2020/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2020/11/News-Release-11-25-2020-1690222963825641.pdf)\n\nNovember 24, 2020 \n\n[Revance to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference](/investors/Press-Releases/news-details/2020/Revance-to-Participate-in-the-Piper-Sandler-32nd-Annual-Virtual-Healthcare-Conference-11-24-2020/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2020/Revance-to-Participate-in-the-Piper-Sandler-32nd-Annual-Virtual-Healthcare-Conference-11-24-2020/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2020/11/News-Release-11-24-2020-1690222963825384.pdf)\n\nNovember 20, 2020 \n\n[Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](/investors/Press-Releases/news-details/2020/Revance-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4-11-20-2020/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2020/Revance-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4-11-20-2020/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2020/11/News-Release-11-20-2020-1690222963825970.pdf)\n\nNovember 10, 2020 \n\n[Revance to Participate in the Stifel 2020 Virtual Healthcare Conference](/investors/Press-Releases/news-details/2020/Revance-to-Participate-in-the-Stifel-2020-Virtual-Healthcare-Conference-11-10-2020/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2020/Revance-to-Participate-in-the-Stifel-2020-Virtual-Healthcare-Conference-11-10-2020/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2020/11/News-Release-11-10-2020-1690222963825590.pdf)\n\nNovember 9, 2020 \n\n[Revance Announces Results of Phase 2 Trial of DaxibotulinumtoxinA for Injection in Plantar Fasciitis](/investors/Press-Releases/news-details/2020/Revance-Announces-Results-of-Phase-2-Trial-of-DaxibotulinumtoxinA-for-Injection-in-Plantar-Fasciitis-11-09-2020/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2020/Revance-Announces-Results-of-Phase-2-Trial-of-DaxibotulinumtoxinA-for-Injection-in-Plantar-Fasciitis-11-09-2020/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2020/11/News-Release-11-09-2020-169022296382575.pdf)\n\nNovember 9, 2020 \n\n[Revance Reports Third Quarter 2020 Financial Results and Provides Corporate Update](/investors/Press-Releases/news-details/2020/Revance-Reports-Third-Quarter-2020-Financial-Results-and-Provides-Corporate-Update-11-09-2020/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2020/Revance-Reports-Third-Quarter-2020-Financial-Results-and-Provides-Corporate-Update-11-09-2020/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2020/11/News-Release-11-09-2020-1690222963825511.pdf)\n\nNovember 3, 2020 \n\n[Revance to Participate in the Credit Suisse 29th Annual Healthcare Conference](/investors/Press-Releases/news-details/2020/Revance-to-Participate-in-the-Credit-Suisse-29th-Annual-Healthcare-Conference-11-03-2020/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2020/Revance-to-Participate-in-the-Credit-Suisse-29th-Annual-Healthcare-Conference-11-03-2020/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2020/11/News-Release-11-03-2020-169022296382510.pdf)\n\nNovember 2, 2020 \n\n[Revance to Release Third Quarter 2020 Financial Results on Monday, November 9, 2020](/investors/Press-Releases/news-details/2020/Revance-to-Release-Third-Quarter-2020-Financial-Results-on-Monday-November-9-2020-11-02-2020/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2020/Revance-to-Release-Third-Quarter-2020-Financial-Results-on-Monday-November-9-2020-11-02-2020/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2020/11/News-Release-11-02-2020-1690222963825332.pdf)\n\nOctober 23, 2020 \n\n[Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](/investors/Press-Releases/news-details/2020/Revance-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4-10-23-2020/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2020/Revance-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4-10-23-2020/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2020/10/News-Release-10-23-2020-1690222963825173.pdf)\n\nOctober 14, 2020 \n\n[Revance Reports Positive Results from ASPEN-1 Phase 3 Trial of DaxibotulinumtoxinA for Injection in Cervical Dystonia](/investors/Press-Releases/news-details/2020/Revance-Reports-Positive-Results-from-ASPEN-1-Phase-3-Trial-of-DaxibotulinumtoxinA-for-Injection-in-Cervical-Dystonia-10-14-2020/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2020/Revance-Reports-Positive-Results-from-ASPEN-1-Phase-3-Trial-of-DaxibotulinumtoxinA-for-Injection-in-Cervical-Dystonia-10-14-2020/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2020/10/News-Release-10-14-2020-1690222970620872.pdf)\n\nOctober 6, 2020 \n\n[Revance to Present Three New Abstracts Evaluating DaxibotulinumtoxinA for Injection and Two ePosters Evaluating the RHA® Collection During the American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting](/investors/Press-Releases/news-details/2020/Revance-to-Present-Three-New-Abstracts-Evaluating-DaxibotulinumtoxinA-for-Injection-and-Two-ePosters-Evaluating-the-RHA-Collection-During-the-American-Society-for-Dermatologic-Surgery-ASDS-Virtual-Annual-Meeting-10-06-2020/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2020/Revance-to-Present-Three-New-Abstracts-Evaluating-DaxibotulinumtoxinA-for-Injection-and-Two-ePosters-Evaluating-the-RHA-Collection-During-the-American-Society-for-Dermatologic-Surgery-ASDS-Virtual-Annual-Meeting-10-06-2020/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2020/10/News-Release-10-06-2020-169022297062029.pdf)\n\nSeptember 23, 2020 \n\n[Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](/investors/Press-Releases/news-details/2020/Revance-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4-09-23-2020/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2020/Revance-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4-09-23-2020/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2020/09/News-Release-09-23-2020-1690222970620837.pdf)\n\nSeptember 8, 2020 \n\n[Revance to Participate in the Morgan Stanley 18th Annual Global Healthcare Conference](/investors/Press-Releases/news-details/2020/Revance-to-Participate-in-the-Morgan-Stanley-18th-Annual-Global-Healthcare-Conference-09-08-2020/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2020/Revance-to-Participate-in-the-Morgan-Stanley-18th-Annual-Global-Healthcare-Conference-09-08-2020/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2020/09/News-Release-09-08-2020-1690222970620548.pdf)\n\nSeptember 2, 2020 \n\n[Revance to Participate in the Wells Fargo Securities Healthcare Conference](/investors/Press-Releases/news-details/2020/Revance-to-Participate-in-the-Wells-Fargo-Securities-Healthcare-Conference-09-02-2020/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2020/Revance-to-Participate-in-the-Wells-Fargo-Securities-Healthcare-Conference-09-02-2020/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2020/09/News-Release-09-02-2020-1690222970620287.pdf)\n\nAugust 25, 2020 \n\n[Revance Commercial Infrastructure Established and Positioned to Launch Prestige Aesthetics Portfolio with the RHA® Collection of Dermal Fillers](/investors/Press-Releases/news-details/2020/Revance-Commercial-Infrastructure-Established-and-Positioned-to-Launch-Prestige-Aesthetics-Portfolio-with-the-RHA-Collection-of-Dermal-Fillers-08-25-2020/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2020/Revance-Commercial-Infrastructure-Established-and-Positioned-to-Launch-Prestige-Aesthetics-Portfolio-with-the-RHA-Collection-of-Dermal-Fillers-08-25-2020/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2020/08/News-Release-08-25-2020-1690222970620284.pdf)\n\nAugust 11, 2020 \n\n[Revance Announces Two Peer-Reviewed Publications Reporting Safety and Efficacy Results from the SAKURA 3 Open-Label Safety Study in Dermatologic Surgery](/investors/Press-Releases/news-details/2020/Revance-Announces-Two-Peer-Reviewed-Publications-Reporting-Safety-and-Efficacy-Results-from-the-SAKURA-3-Open-Label-Safety-Study-in-Dermatologic-Surgery-08-11-2020/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2020/Revance-Announces-Two-Peer-Reviewed-Publications-Reporting-Safety-and-Efficacy-Results-from-the-SAKURA-3-Open-Label-Safety-Study-in-Dermatologic-Surgery-08-11-2020/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2020/08/News-Release-08-11-2020-1690222970620650.pdf)\n\nAugust 6, 2020 \n\n[Revance Reports Second Quarter 2020 Financial Results, Provides Corporate Update](/investors/Press-Releases/news-details/2020/Revance-Reports-Second-Quarter-2020-Financial-Results-Provides-Corporate-Update-08-06-2020/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2020/Revance-Reports-Second-Quarter-2020-Financial-Results-Provides-Corporate-Update-08-06-2020/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2020/08/News-Release-08-06-2020-169022297062097.pdf)\n\nJuly 30, 2020 \n\n[Revance to Release Second Quarter 2020 Financial Results on Thursday, August 6, 2020](/investors/Press-Releases/news-details/2020/Revance-to-Release-Second-Quarter-2020-Financial-Results-on-Thursday-August-6-2020-07-30-2020/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2020/Revance-to-Release-Second-Quarter-2020-Financial-Results-on-Thursday-August-6-2020-07-30-2020/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2020/07/News-Release-07-30-2020-169022297062013.pdf)\n\nJuly 23, 2020 \n\n[Revance Completes Previously Announced Acquisition of HintMD and its Proprietary Fintech Platform for Aesthetic Practices](/investors/Press-Releases/news-details/2020/Revance-Completes-Previously-Announced-Acquisition-of-HintMD-and-its-Proprietary-Fintech-Platform-for-Aesthetic-Practices-07-23-2020/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2020/Revance-Completes-Previously-Announced-Acquisition-of-HintMD-and-its-Proprietary-Fintech-Platform-for-Aesthetic-Practices-07-23-2020/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2020/07/News-Release-07-23-2020-1690222970620120.pdf)\n\nJune 30, 2020 \n\n[Revance Announces Last Patient Enrolled in Modified JUNIPER Phase 2 Upper Limb Spasticity Trial of DaxibotulinumtoxinA for Injection](/investors/Press-Releases/news-details/2020/Revance-Announces-Last-Patient-Enrolled-in-Modified-JUNIPER-Phase-2-Upper-Limb-Spasticity-Trial-of-DaxibotulinumtoxinA-for-Injection-06-30-2020/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2020/Revance-Announces-Last-Patient-Enrolled-in-Modified-JUNIPER-Phase-2-Upper-Limb-Spasticity-Trial-of-DaxibotulinumtoxinA-for-Injection-06-30-2020/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2020/06/News-Release-06-30-2020-1690222977180907.pdf)\n\nJune 30, 2020 \n\n[Revance Announces Positive Results in Two Phase 2a Studies of DaxibotulinumtoxinA For Injection for the Treatment of Forehead Lines and Crow’s Feet, Respectively](/investors/Press-Releases/news-details/2020/Revance-Announces-Positive-Results-in-Two-Phase-2a-Studies-of-DaxibotulinumtoxinA-For-Injection-for-the-Treatment-of-Forehead-Lines-and-Crows-Feet-Respectively-06-30-2020/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2020/Revance-Announces-Positive-Results-in-Two-Phase-2a-Studies-of-DaxibotulinumtoxinA-For-Injection-for-the-Treatment-of-Forehead-Lines-and-Crows-Feet-Respectively-06-30-2020/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2020/06/News-Release-06-30-2020-1690222977180232.pdf)\n\nJune 4, 2020 \n\n[Revance to Participate in the 40th Annual William Blair Growth Stock Conference](/investors/Press-Releases/news-details/2020/Revance-to-Participate-in-the-40th-Annual-William-Blair-Growth-Stock-Conference-06-04-2020/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2020/Revance-to-Participate-in-the-40th-Annual-William-Blair-Growth-Stock-Conference-06-04-2020/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2020/06/News-Release-06-04-2020-1690222977180826.pdf)\n\nJune 2, 2020 \n\n[Revance to Present at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast](/investors/Press-Releases/news-details/2020/Revance-to-Present-at-the-Goldman-Sachs-41st-Annual-Global-Healthcare-Conference-Webcast-06-02-2020/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2020/Revance-to-Present-at-the-Goldman-Sachs-41st-Annual-Global-Healthcare-Conference-Webcast-06-02-2020/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2020/06/News-Release-06-02-2020-1690222977180371.pdf)\n\nJune 1, 2020 \n\n[Revance and Mylan to Advance Development Program for Biosimilar to BOTOX®](/investors/Press-Releases/news-details/2020/Revance-and-Mylan-to-Advance-Development-Program-for-Biosimilar-to-BOTOX-06-01-2020/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2020/Revance-and-Mylan-to-Advance-Development-Program-for-Biosimilar-to-BOTOX-06-01-2020/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2020/06/News-Release-06-01-2020-1690222977180281.pdf)\n\nMay 19, 2020 \n\n[Revance Announces Agreement to Acquire HintMD and its Proprietary Fintech Platform for Aesthetic Practices](/investors/Press-Releases/news-details/2020/Revance-Announces-Agreement-to-Acquire-HintMD-and-its-Proprietary-Fintech-Platform-for-Aesthetic-Practices-05-19-2020/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2020/Revance-Announces-Agreement-to-Acquire-HintMD-and-its-Proprietary-Fintech-Platform-for-Aesthetic-Practices-05-19-2020/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2020/05/News-Release-05-19-2020-1690222977180779.pdf)\n\nMay 7, 2020 \n\n[Revance Reports First Quarter 2020 Financial Results, Provides Corporate Update](/investors/Press-Releases/news-details/2020/Revance-Reports-First-Quarter-2020-Financial-Results-Provides-Corporate-Update-05-07-2020/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2020/Revance-Reports-First-Quarter-2020-Financial-Results-Provides-Corporate-Update-05-07-2020/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2020/05/News-Release-05-07-2020-1690222977180885.pdf)\n\nMay 1, 2020 \n\n[Revance and Mylan Biosimilar to BOTOX® Program Decision to Extend Beyond April 30, 2020](/investors/Press-Releases/news-details/2020/Revance-and-Mylan-Biosimilar-to-BOTOX-Program-Decision-to-Extend-Beyond-April-30-2020-05-01-2020/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2020/Revance-and-Mylan-Biosimilar-to-BOTOX-Program-Decision-to-Extend-Beyond-April-30-2020-05-01-2020/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2020/05/News-Release-05-01-2020-1690222977180107.pdf)\n\nApril 30, 2020 \n\n[Revance to Release First Quarter 2020 Financial Results on Thursday, May 7, 2020](/investors/Press-Releases/news-details/2020/Revance-to-Release-First-Quarter-2020-Financial-Results-on-Thursday-May-7-2020-04-30-2020/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2020/Revance-to-Release-First-Quarter-2020-Financial-Results-on-Thursday-May-7-2020-04-30-2020/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2020/04/News-Release-04-30-2020-1690222977180535.pdf)\n\nApril 7, 2020 \n\n[Revance to Participate in the 19th Annual Needham Virtual Healthcare Conference](/investors/Press-Releases/news-details/2020/Revance-to-Participate-in-the-19th-Annual-Needham-Virtual-Healthcare-Conference-04-07-2020/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2020/Revance-to-Participate-in-the-19th-Annual-Needham-Virtual-Healthcare-Conference-04-07-2020/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2020/04/News-Release-04-07-2020-1690222977180168.pdf)\n\nMarch 26, 2020 \n\n[Revance Provides Corporate Update in Light of COVID-19](/investors/Press-Releases/news-details/2020/Revance-Provides-Corporate-Update-in-Light-of-COVID-19-03-26-2020/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2020/Revance-Provides-Corporate-Update-in-Light-of-COVID-19-03-26-2020/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2020/03/News-Release-03-26-2020-1690222983707241.pdf)\n\nMarch 3, 2020 \n\n[Revance to Participate in the Barclays Global Healthcare Conference 2020](/investors/Press-Releases/news-details/2020/Revance-to-Participate-in-the-Barclays-Global-Healthcare-Conference-2020-03-03-2020/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2020/Revance-to-Participate-in-the-Barclays-Global-Healthcare-Conference-2020-03-03-2020/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2020/03/News-Release-03-03-2020-1690222983707753.pdf)\n\nFebruary 25, 2020 \n\n[Revance to Participate in the Cowen 40th Annual Health Care Conference](/investors/Press-Releases/news-details/2020/Revance-to-Participate-in-the-Cowen-40th-Annual-Health-Care-Conference-02-25-2020/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2020/Revance-to-Participate-in-the-Cowen-40th-Annual-Health-Care-Conference-02-25-2020/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2020/02/News-Release-02-25-2020-1690222983707182.pdf)\n\nFebruary 24, 2020 \n\n[Revance Reports Fourth Quarter and Full Year 2019 Financial Results, Provides Corporate Update](/investors/Press-Releases/news-details/2020/Revance-Reports-Fourth-Quarter-and-Full-Year-2019-Financial-Results-Provides-Corporate-Update-02-24-2020/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2020/Revance-Reports-Fourth-Quarter-and-Full-Year-2019-Financial-Results-Provides-Corporate-Update-02-24-2020/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2020/02/News-Release-02-24-2020-1690222983707933.pdf)\n\nFebruary 14, 2020 \n\n[Revance to Release Fourth Quarter and Full Year 2019 Financial Results on Monday, February 24, 2020](/investors/Press-Releases/news-details/2020/Revance-to-Release-Fourth-Quarter-and-Full-Year-2019-Financial-Results-on-Monday-February-24-2020-02-14-2020/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2020/Revance-to-Release-Fourth-Quarter-and-Full-Year-2019-Financial-Results-on-Monday-February-24-2020-02-14-2020/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2020/02/News-Release-02-14-2020-169022298370762.pdf)\n\nFebruary 12, 2020 \n\n[Revance Announces Pricing of $250 Million of Convertible Senior Notes Due 2027](/investors/Press-Releases/news-details/2020/Revance-Announces-Pricing-of-250-Million-of-Convertible-Senior-Notes-Due-2027-02-12-2020/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2020/Revance-Announces-Pricing-of-250-Million-of-Convertible-Senior-Notes-Due-2027-02-12-2020/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2020/02/News-Release-02-12-2020-1690222983707761.pdf)\n\nFebruary 10, 2020 \n\n[Revance Announces Proposed Private Offering of $200 Million of Convertible Senior Notes Due 2027](/investors/Press-Releases/news-details/2020/Revance-Announces-Proposed-Private-Offering-of-200-Million-of-Convertible-Senior-Notes-Due-2027-02-10-2020/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2020/Revance-Announces-Proposed-Private-Offering-of-200-Million-of-Convertible-Senior-Notes-Due-2027-02-10-2020/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2020/02/News-Release-02-10-2020-1690222983708741.pdf)\n\nFebruary 6, 2020 \n\n[Revance Announces U.S. FDA Acceptance of Biologics License Application (BLA) for DAXI to Treat Glabellar (Frown) Lines](/investors/Press-Releases/news-details/2020/Revance-Announces-U.S.-FDA-Acceptance-of-Biologics-License-Application-BLA-for-DAXI-to-Treat-Glabellar-Frown-Lines-02-06-2020/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2020/Revance-Announces-U.S.-FDA-Acceptance-of-Biologics-License-Application-BLA-for-DAXI-to-Treat-Glabellar-Frown-Lines-02-06-2020/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2020/02/News-Release-02-06-2020-1690222983708220.pdf)\n\nJanuary 10, 2020 \n\n[Revance Announces Transformative Aesthetics Portfolio Transaction with Exclusive U.S. Distribution Agreement of FDA-Approved Dermal Fillers from TEOXANE SA](/investors/Press-Releases/news-details/2020/Revance-Announces-Transformative-Aesthetics-Portfolio-Transaction-with-Exclusive-U.S.-Distribution-Agreement-of-FDA-Approved-Dermal-Fillers-from-TEOXANE-SA-01-10-2020/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2020/Revance-Announces-Transformative-Aesthetics-Portfolio-Transaction-with-Exclusive-U.S.-Distribution-Agreement-of-FDA-Approved-Dermal-Fillers-from-TEOXANE-SA-01-10-2020/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2020/01/News-Release-01-10-2020-1690222983708748.pdf)\n\nJanuary 9, 2020 \n\n[Revance to Participate in the 38th Annual J.P. Morgan Healthcare Conference](/investors/Press-Releases/news-details/2020/Revance-to-Participate-in-the-38th-Annual-J.P.-Morgan-Healthcare-Conference-01-09-2020/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2020/Revance-to-Participate-in-the-38th-Annual-J.P.-Morgan-Healthcare-Conference-01-09-2020/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2020/01/News-Release-01-09-2020-1690222983708915.pdf)\n\nJanuary 9, 2020 \n\n[Revance Provides Corporate Update and Anticipated Milestones for 2020](/investors/Press-Releases/news-details/2020/Revance-Provides-Corporate-Update-and-Anticipated-Milestones-for-2020-01-09-2020/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2020/Revance-Provides-Corporate-Update-and-Anticipated-Milestones-for-2020-01-09-2020/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2020/01/News-Release-01-09-2020-1690222990289643.pdf)\n\nDecember 5, 2019 \n\n[Revance Announces Publication of Pooled Results from Phase 3 Trials for Glabellar Lines in the Journal of the American Academy of Dermatology](/investors/Press-Releases/news-details/2019/Revance-Announces-Publication-of-Pooled-Results-from-Phase-3-Trials-for-Glabellar-Lines-in-the-Journal-of-the-American-Academy-of-Dermatology-12-05-2019/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2019/Revance-Announces-Publication-of-Pooled-Results-from-Phase-3-Trials-for-Glabellar-Lines-in-the-Journal-of-the-American-Academy-of-Dermatology-12-05-2019/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2019/12/News-Release-12-05-2019-1690222990289652.pdf)\n\nDecember 4, 2019 \n\n[Revance Announces Pricing of Public Offering of Common Stock](/investors/Press-Releases/news-details/2019/Revance-Announces-Pricing-of-Public-Offering-of-Common-Stock-12-04-2019/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2019/Revance-Announces-Pricing-of-Public-Offering-of-Common-Stock-12-04-2019/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2019/12/News-Release-12-04-2019-1690222990289405.pdf)\n\nDecember 3, 2019 \n\n[Revance Announces Proposed Public Offering of Common Stock](/investors/Press-Releases/news-details/2019/Revance-Announces-Proposed-Public-Offering-of-Common-Stock-12-03-2019/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2019/Revance-Announces-Proposed-Public-Offering-of-Common-Stock-12-03-2019/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2019/12/News-Release-12-03-2019-1690222990289452.pdf)\n\nDecember 2, 2019 \n\n[Revance Promotes Dustin Sjuts to Chief Commercial Officer, Aesthetics & Therapeutics](/investors/Press-Releases/news-details/2019/Revance-Promotes-Dustin-Sjuts-to-Chief-Commercial-Officer-Aesthetics-Therapeutics-12-02-2019/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2019/Revance-Promotes-Dustin-Sjuts-to-Chief-Commercial-Officer-Aesthetics-Therapeutics-12-02-2019/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2019/12/News-Release-12-02-2019-1690222990289631.pdf)\n\nNovember 25, 2019 \n\n[Revance Submits Biologics License Application (BLA) to the FDA for DAXI to Treat Glabellar (Frown) Lines](/investors/Press-Releases/news-details/2019/Revance-Submits-Biologics-License-Application-BLA-to-the-FDA-for-DAXI-to-Treat-Glabellar-Frown-Lines-11-25-2019/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2019/Revance-Submits-Biologics-License-Application-BLA-to-the-FDA-for-DAXI-to-Treat-Glabellar-Frown-Lines-11-25-2019/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2019/11/News-Release-11-25-2019-1690222990289369.pdf)\n\nNovember 12, 2019 \n\n[Revance to Participate in the Stifel 2019 Healthcare Conference](/investors/Press-Releases/news-details/2019/Revance-to-Participate-in-the-Stifel-2019-Healthcare-Conference-11-12-2019/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2019/Revance-to-Participate-in-the-Stifel-2019-Healthcare-Conference-11-12-2019/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2019/11/News-Release-11-12-2019-1690222990289899.pdf)\n\nNovember 6, 2019 \n\n[Revance to Participate in the Credit Suisse 28th Annual Healthcare Conference](/investors/Press-Releases/news-details/2019/Revance-to-Participate-in-the-Credit-Suisse-28th-Annual-Healthcare-Conference-11-06-2019/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2019/Revance-to-Participate-in-the-Credit-Suisse-28th-Annual-Healthcare-Conference-11-06-2019/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2019/11/News-Release-11-06-2019-1690222990289440.pdf)\n\nNovember 4, 2019 \n\n[Revance Completes Enrollment in ASPEN-1 Phase 3 Pivotal Trial for Cervical Dystonia](/investors/Press-Releases/news-details/2019/Revance-Completes-Enrollment-in-ASPEN-1-Phase-3-Pivotal-Trial-for-Cervical-Dystonia-11-04-2019/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2019/Revance-Completes-Enrollment-in-ASPEN-1-Phase-3-Pivotal-Trial-for-Cervical-Dystonia-11-04-2019/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2019/11/News-Release-11-04-2019-1690222990289364.pdf)\n\nNovember 4, 2019 \n\n[Revance Announces Publication of SAKURA 1 and SAKURA 2 Results in Plastic and Reconstructive Surgery](/investors/Press-Releases/news-details/2019/Revance-Announces-Publication-of-SAKURA-1-and-SAKURA-2-Results-in-Plastic-and-Reconstructive-Surgery-11-04-2019/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2019/Revance-Announces-Publication-of-SAKURA-1-and-SAKURA-2-Results-in-Plastic-and-Reconstructive-Surgery-11-04-2019/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2019/11/News-Release-11-04-2019-16902229971929.pdf)\n\nNovember 4, 2019 \n\n[Revance Reports Third Quarter 2019 Financial Results, Provides Corporate Update](/investors/Press-Releases/news-details/2019/Revance-Reports-Third-Quarter-2019-Financial-Results-Provides-Corporate-Update-11-04-2019/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2019/Revance-Reports-Third-Quarter-2019-Financial-Results-Provides-Corporate-Update-11-04-2019/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2019/11/News-Release-11-04-2019-16902229902899.pdf)\n\nOctober 28, 2019 \n\n[Revance to Release Third Quarter 2019 Financial Results on Monday, November 4, 2019](/investors/Press-Releases/news-details/2019/Revance-to-Release-Third-Quarter-2019-Financial-Results-on-Monday-November-4-2019-10-28-2019/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2019/Revance-to-Release-Third-Quarter-2019-Financial-Results-on-Monday-November-4-2019-10-28-2019/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2019/10/News-Release-10-28-2019-1690222997193481.pdf)\n\nOctober 23, 2019 \n\n[Revance to Present Clinical Data Highlighting the Efficacy and Safety of DAXI at the ASDS 2019 Annual Meeting](/investors/Press-Releases/news-details/2019/Revance-to-Present-Clinical-Data-Highlighting-the-Efficacy-and-Safety-of-DAXI-at-the-ASDS-2019-Annual-Meeting-10-23-2019/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2019/Revance-to-Present-Clinical-Data-Highlighting-the-Efficacy-and-Safety-of-DAXI-at-the-ASDS-2019-Annual-Meeting-10-23-2019/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2019/10/News-Release-10-23-2019-1690222997193762.pdf)\n\nOctober 14, 2019 \n\n[Revance Appoints Mark J. Foley as President and CEO, Replacing Dan Browne](/investors/Press-Releases/news-details/2019/Revance-Appoints-Mark-J.-Foley-as-President-and-CEO-Replacing-Dan-Browne-10-14-2019/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2019/Revance-Appoints-Mark-J.-Foley-as-President-and-CEO-Replacing-Dan-Browne-10-14-2019/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2019/10/News-Release-10-14-2019-1690222997193502.pdf)\n\nOctober 2, 2019 \n\n[Revance Earns Great Place to Work® Certification for Second Year](/investors/Press-Releases/news-details/2019/Revance-Earns-Great-Place-to-Work-Certification-for-Second-Year-10-02-2019/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2019/Revance-Earns-Great-Place-to-Work-Certification-for-Second-Year-10-02-2019/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2019/10/News-Release-10-02-2019-1690222997193185.pdf)\n\nSeptember 25, 2019 \n\n[Revance to Participate in the 2019 Cantor Global Healthcare Conference](/investors/Press-Releases/news-details/2019/Revance-to-Participate-in-the-2019-Cantor-Global-Healthcare-Conference-09-25-2019/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2019/Revance-to-Participate-in-the-2019-Cantor-Global-Healthcare-Conference-09-25-2019/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2019/09/News-Release-09-25-2019-1690222997193394.pdf)\n\nSeptember 4, 2019 \n\n[Revance to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference](/investors/Press-Releases/news-details/2019/Revance-to-Participate-in-the-Morgan-Stanley-17th-Annual-Global-Healthcare-Conference-09-04-2019/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2019/Revance-to-Participate-in-the-Morgan-Stanley-17th-Annual-Global-Healthcare-Conference-09-04-2019/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2019/09/News-Release-09-04-2019-1690222997193243.pdf)\n\nAugust 28, 2019 \n\n[Revance to Participate in the Wells Fargo 14th Annual Healthcare Conference](/investors/Press-Releases/news-details/2019/Revance-to-Participate-in-the-Wells-Fargo-14th-Annual-Healthcare-Conference-08-28-2019/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2019/Revance-to-Participate-in-the-Wells-Fargo-14th-Annual-Healthcare-Conference-08-28-2019/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2019/08/News-Release-08-28-2019-1690222997193406.pdf)\n\nAugust 5, 2019 \n\n[Revance Reports Second Quarter 2019 Financial Results, Provides Corporate Update](/investors/Press-Releases/news-details/2019/Revance-Reports-Second-Quarter-2019-Financial-Results-Provides-Corporate-Update-08-05-2019/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2019/Revance-Reports-Second-Quarter-2019-Financial-Results-Provides-Corporate-Update-08-05-2019/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2019/08/News-Release-08-05-2019-1690222997193915.pdf)\n\nJuly 29, 2019 \n\n[Revance to Release Second Quarter 2019 Financial Results on Monday, August 5, 2019](/investors/Press-Releases/news-details/2019/Revance-to-Release-Second-Quarter-2019-Financial-Results-on-Monday-August-5-2019-07-29-2019/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2019/Revance-to-Release-Second-Quarter-2019-Financial-Results-on-Monday-August-5-2019-07-29-2019/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2019/07/News-Release-07-29-2019-1690222997193473.pdf)\n\nJuly 17, 2019 \n\n[Revance Adds Life Sciences Audit Executive Chris Nolet to Board of Directors](/investors/Press-Releases/news-details/2019/Revance-Adds-Life-Sciences-Audit-Executive-Chris-Nolet-to-Board-of-Directors-07-17-2019/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2019/Revance-Adds-Life-Sciences-Audit-Executive-Chris-Nolet-to-Board-of-Directors-07-17-2019/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2019/07/News-Release-07-17-2019-169022300373188.pdf)\n\nJune 6, 2019 \n\n[Revance Adds Iconic Brand Builder Jill Beraud to Board of Directors](/investors/Press-Releases/news-details/2019/Revance-Adds-Iconic-Brand-Builder-Jill-Beraud-to-Board-of-Directors-06-06-2019/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2019/Revance-Adds-Iconic-Brand-Builder-Jill-Beraud-to-Board-of-Directors-06-06-2019/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2019/06/News-Release-06-06-2019-1690223003731426.pdf)\n\nJune 4, 2019 \n\n[Revance to Participate in the Goldman Sachs 40th Annual Global Healthcare Conference](/investors/Press-Releases/news-details/2019/Revance-to-Participate-in-the-Goldman-Sachs-40th-Annual-Global-Healthcare-Conference-06-04-2019/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2019/Revance-to-Participate-in-the-Goldman-Sachs-40th-Annual-Global-Healthcare-Conference-06-04-2019/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2019/06/News-Release-06-04-2019-169022300373178.pdf)\n\nMay 14, 2019 \n\n[Revance to Participate in the RBC Capital Markets 2019 Healthcare Conference](/investors/Press-Releases/news-details/2019/Revance-to-Participate-in-the-RBC-Capital-Markets-2019-Healthcare-Conference-05-14-2019/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2019/Revance-to-Participate-in-the-RBC-Capital-Markets-2019-Healthcare-Conference-05-14-2019/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2019/05/News-Release-05-14-2019-1690223003731161.pdf)\n\nMay 8, 2019 \n\n[Revance Reports First Quarter 2019 Financial Results and Provides Corporate Update](/investors/Press-Releases/news-details/2019/Revance-Reports-First-Quarter-2019-Financial-Results-and-Provides-Corporate-Update-05-08-2019/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2019/Revance-Reports-First-Quarter-2019-Financial-Results-and-Provides-Corporate-Update-05-08-2019/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2019/05/News-Release-05-08-2019-1690223003731661.pdf)\n\nApril 24, 2019 \n\n[Revance to Release First Quarter 2019 Financial Results on Wednesday, May 8, 2019](/investors/Press-Releases/news-details/2019/Revance-to-Release-First-Quarter-2019-Financial-Results-on-Wednesday-May-8-2019-04-24-2019/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2019/Revance-to-Release-First-Quarter-2019-Financial-Results-on-Wednesday-May-8-2019-04-24-2019/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2019/04/News-Release-04-24-2019-1690223003731478.pdf)\n\nApril 9, 2019 \n\n[Revance Appoints Former Allergan Marketing Veteran Taryn Conway as Vice President of Marketing](/investors/Press-Releases/news-details/2019/Revance-Appoints-Former-Allergan-Marketing-Veteran-Taryn-Conway-as-Vice-President-of-Marketing-04-09-2019/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2019/Revance-Appoints-Former-Allergan-Marketing-Veteran-Taryn-Conway-as-Vice-President-of-Marketing-04-09-2019/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2019/04/News-Release-04-09-2019-1690223003731430.pdf)\n\nApril 8, 2019 \n\n[SAKURA 3 Trial Results Presented on Podium at World’s Largest Medical Aesthetic Conference](/investors/Press-Releases/news-details/2019/SAKURA-3-Trial-Results-Presented-on-Podium-at-Worlds-Largest-Medical-Aesthetic-Conference-04-08-2019/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2019/SAKURA-3-Trial-Results-Presented-on-Podium-at-Worlds-Largest-Medical-Aesthetic-Conference-04-08-2019/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2019/04/News-Release-04-08-2019-1690223003731414.pdf)\n\nApril 2, 2019 \n\n[Revance to Participate in the Needham Healthcare Conference](/investors/Press-Releases/news-details/2019/Revance-to-Participate-in-the-Needham-Healthcare-Conference-04-02-2019/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2019/Revance-to-Participate-in-the-Needham-Healthcare-Conference-04-02-2019/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2019/04/News-Release-04-02-2019-1690223003731182.pdf)\n\nMarch 5, 2019 \n\n[Revance to Participate in Upcoming Investor Conferences](/investors/Press-Releases/news-details/2019/Revance-to-Participate-in-Upcoming-Investor-Conferences-03-05-2019/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2019/Revance-to-Participate-in-Upcoming-Investor-Conferences-03-05-2019/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2019/03/News-Release-03-05-2019-1690223003731505.pdf)\n\nFebruary 26, 2019 \n\n[Revance Releases Fourth Quarter and Full Year 2018 Results](/investors/Press-Releases/news-details/2019/Revance-Releases-Fourth-Quarter-and-Full-Year-2018-Results-02-26-2019/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2019/Revance-Releases-Fourth-Quarter-and-Full-Year-2018-Results-02-26-2019/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2019/02/News-Release-02-26-2019-1690223010415428.pdf)\n\nFebruary 12, 2019 \n\n[Revance to Release Fourth Quarter and Full Year 2018 Financial Results on Tuesday, February 26, 2019](/investors/Press-Releases/news-details/2019/Revance-to-Release-Fourth-Quarter-and-Full-Year-2018-Financial-Results-on-Tuesday-February-26-2019-02-12-2019/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2019/Revance-to-Release-Fourth-Quarter-and-Full-Year-2018-Financial-Results-on-Tuesday-February-26-2019-02-12-2019/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2019/02/News-Release-02-12-2019-1690223010415177.pdf)\n\nJanuary 22, 2019 \n\n[Revance Announces Closing of Public Offering of Common Stock](/investors/Press-Releases/news-details/2019/Revance-Announces-Closing-of-Public-Offering-of-Common-Stock-01-22-2019/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2019/Revance-Announces-Closing-of-Public-Offering-of-Common-Stock-01-22-2019/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2019/01/News-Release-01-22-2019-1690223010415230.pdf)\n\nJanuary 17, 2019 \n\n[Revance Announces Pricing of Public Offering of Common Stock](/investors/Press-Releases/news-details/2019/Revance-Announces-Pricing-of-Public-Offering-of-Common-Stock-01-17-2019/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2019/Revance-Announces-Pricing-of-Public-Offering-of-Common-Stock-01-17-2019/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2019/01/News-Release-01-17-2019-1690223010415780.pdf)\n\nJanuary 15, 2019 \n\n[Revance Announces Proposed Public Offering of Common Stock](/investors/Press-Releases/news-details/2019/Revance-Announces-Proposed-Public-Offering-of-Common-Stock-01-15-2019/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2019/Revance-Announces-Proposed-Public-Offering-of-Common-Stock-01-15-2019/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2019/01/News-Release-01-15-2019-1690223010415681.pdf)\n\nJanuary 15, 2019 \n\n[Revance Announces Ground-Breaking Data Presentations at Leading International Neurotoxin Conference](/investors/Press-Releases/news-details/2019/Revance-Announces-Ground-Breaking-Data-Presentations-at-Leading-International-Neurotoxin-Conference-01-15-2019/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2019/Revance-Announces-Ground-Breaking-Data-Presentations-at-Leading-International-Neurotoxin-Conference-01-15-2019/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2019/01/News-Release-01-15-2019-1690223010415836.pdf)\n\nJanuary 7, 2019 \n\n[Revance Highlights Recent Regulatory Progress and Provides Anticipated 2019 Milestones](/investors/Press-Releases/news-details/2019/Revance-Highlights-Recent-Regulatory-Progress-and-Provides-Anticipated-2019-Milestones-01-07-2019/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2019/Revance-Highlights-Recent-Regulatory-Progress-and-Provides-Anticipated-2019-Milestones-01-07-2019/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2019/01/News-Release-01-07-2019-1690223010415309.pdf)\n\nDecember 4, 2018 \n\n[Revance Announces China Market License Agreement with Fosun Pharma for RT002](/investors/Press-Releases/news-details/2018/Revance-Announces-China-Market-License-Agreement-with-Fosun-Pharma-for-RT002-12-04-2018/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2018/Revance-Announces-China-Market-License-Agreement-with-Fosun-Pharma-for-RT002-12-04-2018/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2018/12/News-Release-12-04-2018-1690223010416326.pdf)\n\nDecember 4, 2018 \n\n[Revance’s RT002 Demonstrates Unprecedented Efficacy and Duration In Largest-Ever Aesthetic Neuromodulator Clinical Program](/investors/Press-Releases/news-details/2018/Revances-RT002-Demonstrates-Unprecedented-Efficacy-and-Duration-In-Largest-Ever-Aesthetic-Neuromodulator-Clinical-Program-12-04-2018/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2018/Revances-RT002-Demonstrates-Unprecedented-Efficacy-and-Duration-In-Largest-Ever-Aesthetic-Neuromodulator-Clinical-Program-12-04-2018/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2018/12/News-Release-12-04-2018-1690223010416744.pdf)\n\nNovember 20, 2018 \n\n[Revance to Participate in Upcoming Investor Conferences](/investors/Press-Releases/news-details/2018/Revance-to-Participate-in-Upcoming-Investor-Conferences-11-20-2018/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2018/Revance-to-Participate-in-Upcoming-Investor-Conferences-11-20-2018/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2018/11/News-Release-11-20-2018-1690223010416521.pdf)\n\nNovember 7, 2018 \n\n[Revance to Participate in the Credit Suisse Healthcare Conference](/investors/Press-Releases/news-details/2018/Revance-to-Participate-in-the-Credit-Suisse-Healthcare-Conference-11-07-2018/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2018/Revance-to-Participate-in-the-Credit-Suisse-Healthcare-Conference-11-07-2018/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2018/11/News-Release-11-07-2018-169022301707630.pdf)\n\nNovember 1, 2018 \n\n[Revance Releases Third Quarter 2018 Results](/investors/Press-Releases/news-details/2018/Revance-Releases-Third-Quarter-2018-Results-11-01-2018/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2018/Revance-Releases-Third-Quarter-2018-Results-11-01-2018/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2018/11/News-Release-11-01-2018-1690223017076290.pdf)\n\nOctober 18, 2018 \n\n[Revance Therapeutics to Release Third Quarter 2018 Financial Results on Thursday, November 1, 2018](/investors/Press-Releases/news-details/2018/Revance-Therapeutics-to-Release-Third-Quarter-2018-Financial-Results-on-Thursday-November-1-2018-10-18-2018/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2018/Revance-Therapeutics-to-Release-Third-Quarter-2018-Financial-Results-on-Thursday-November-1-2018-10-18-2018/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2018/10/News-Release-10-18-2018-1690223017076422.pdf)\n\nOctober 11, 2018 \n\n[Revance Therapeutics Appoints Tobin C. Schilke as Chief Financial Officer](/investors/Press-Releases/news-details/2018/Revance-Therapeutics-Appoints-Tobin-C.-Schilke-as-Chief-Financial-Officer-10-11-2018/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2018/Revance-Therapeutics-Appoints-Tobin-C.-Schilke-as-Chief-Financial-Officer-10-11-2018/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2018/10/News-Release-10-11-2018-1690223017076533.pdf)\n\nSeptember 24, 2018 \n\n[Revance to Participate in the Cantor Fitzgerald 2018 Global Healthcare Conference](/investors/Press-Releases/news-details/2018/Revance-to-Participate-in-the-Cantor-Fitzgerald-2018-Global-Healthcare-Conference-09-24-2018/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2018/Revance-to-Participate-in-the-Cantor-Fitzgerald-2018-Global-Healthcare-Conference-09-24-2018/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2018/09/News-Release-09-24-2018-1690223017076522.pdf)\n\nSeptember 20, 2018 \n\n[Revance Receives Great Place to Work Certification](/investors/Press-Releases/news-details/2018/Revance-Receives-Great-Place-to-Work-Certification-09-20-2018/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2018/Revance-Receives-Great-Place-to-Work-Certification-09-20-2018/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2018/09/News-Release-09-20-2018-1690223017076404.pdf)\n\nAugust 2, 2018 \n\n[Revance Releases Second Quarter 2018 Results](/investors/Press-Releases/news-details/2018/Revance-Releases-Second-Quarter-2018-Results-08-02-2018/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2018/Revance-Releases-Second-Quarter-2018-Results-08-02-2018/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2018/08/News-Release-08-02-2018-1690223017077764.pdf)\n\nJuly 19, 2018 \n\n[Revance Therapeutics to Release Second Quarter 2018 Financial Results on Thursday, August 2, 2018](/investors/Press-Releases/news-details/2018/Revance-Therapeutics-to-Release-Second-Quarter-2018-Financial-Results-on-Thursday-August-2-2018-07-19-2018/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2018/Revance-Therapeutics-to-Release-Second-Quarter-2018-Financial-Results-on-Thursday-August-2-2018-07-19-2018/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2018/07/News-Release-07-19-2018-1690223017077452.pdf)\n\nJune 21, 2018 \n\n[Revance Doses First Patient in ASPEN Phase 3 Clinical Program of RT002 Injectable for the Treatment of Cervical Dystonia](/investors/Press-Releases/news-details/2018/Revance-Doses-First-Patient-in-ASPEN-Phase-3-Clinical-Program-of-RT002-Injectable-for-the-Treatment-of-Cervical-Dystonia-06-21-2018/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2018/Revance-Doses-First-Patient-in-ASPEN-Phase-3-Clinical-Program-of-RT002-Injectable-for-the-Treatment-of-Cervical-Dystonia-06-21-2018/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2018/06/News-Release-06-21-2018-1690223017077975.pdf)\n\nJune 14, 2018 \n\n[Revance to Participate in the JMP Securities Life Sciences Conference 2018](/investors/Press-Releases/news-details/2018/Revance-to-Participate-in-the-JMP-Securities-Life-Sciences-Conference-2018-06-14-2018/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2018/Revance-to-Participate-in-the-JMP-Securities-Life-Sciences-Conference-2018-06-14-2018/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2018/06/News-Release-06-14-2018-1690223017077467.pdf)\n\nJune 5, 2018 \n\n[Revance to Participate in Upcoming Investor Conferences](/investors/Press-Releases/news-details/2018/Revance-to-Participate-in-Upcoming-Investor-Conferences-06-05-2018/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2018/Revance-to-Participate-in-Upcoming-Investor-Conferences-06-05-2018/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2018/06/News-Release-06-05-2018-1690223023701752.pdf)\n\nMay 29, 2018 \n\n[Revance to Participate in the Jefferies 2018 Global Healthcare Conference](/investors/Press-Releases/news-details/2018/Revance-to-Participate-in-the-Jefferies-2018-Global-Healthcare-Conference-05-29-2018/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2018/Revance-to-Participate-in-the-Jefferies-2018-Global-Healthcare-Conference-05-29-2018/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2018/05/News-Release-05-29-2018-1690223023701347.pdf)\n\nMay 29, 2018 \n\n[Revance Announces Departure of Chief Financial Officer](/investors/Press-Releases/news-details/2018/Revance-Announces-Departure-of-Chief-Financial-Officer-05-29-2018/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2018/Revance-Announces-Departure-of-Chief-Financial-Officer-05-29-2018/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2018/05/News-Release-05-29-2018-169022302370118.pdf)\n\nMay 24, 2018 \n\n[Revance Announces Publication of Positive 24-Week Duration of Effect Results from Cervical Dystonia Phase 2 Trial in Movement Disorders Clinical Practice](/investors/Press-Releases/news-details/2018/Revance-Announces-Publication-of-Positive-24-Week-Duration-of-Effect-Results-from-Cervical-Dystonia-Phase-2-Trial-in-Movement-Disorders-Clinical-Practice-05-24-2018/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2018/Revance-Announces-Publication-of-Positive-24-Week-Duration-of-Effect-Results-from-Cervical-Dystonia-Phase-2-Trial-in-Movement-Disorders-Clinical-Practice-05-24-2018/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2018/05/News-Release-05-24-2018-1690223023701975.pdf)\n\nMay 15, 2018 \n\n[Revance to Participate in the UBS Global Healthcare Conference](/investors/Press-Releases/news-details/2018/Revance-to-Participate-in-the-UBS-Global-Healthcare-Conference-05-15-2018/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2018/Revance-to-Participate-in-the-UBS-Global-Healthcare-Conference-05-15-2018/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2018/05/News-Release-05-15-2018-1690223023701970.pdf)\n\nMay 9, 2018 \n\n[Revance Therapeutics Announces Two Recent Additions to Its Management Team](/investors/Press-Releases/news-details/2018/Revance-Therapeutics-Announces-Two-Recent-Additions-to-Its-Management-Team-05-09-2018/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2018/Revance-Therapeutics-Announces-Two-Recent-Additions-to-Its-Management-Team-05-09-2018/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2018/05/News-Release-05-09-2018-1690223023701963.pdf)\n\nMay 8, 2018 \n\n[Revance Releases First Quarter 2018 Results](/investors/Press-Releases/news-details/2018/Revance-Releases-First-Quarter-2018-Results-05-08-2018/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2018/Revance-Releases-First-Quarter-2018-Results-05-08-2018/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2018/05/News-Release-05-08-2018-1690223023701646.pdf)\n\nMay 1, 2018 \n\n[Revance Therapeutics Expands Leadership Team, Appointing Caryn McDowell as SVP, General Counsel & Corporate Secretary](/investors/Press-Releases/news-details/2018/Revance-Therapeutics-Expands-Leadership-Team-Appointing-Caryn-McDowell-as-SVP-General-Counsel-Corporate-Secretary-05-01-2018/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2018/Revance-Therapeutics-Expands-Leadership-Team-Appointing-Caryn-McDowell-as-SVP-General-Counsel-Corporate-Secretary-05-01-2018/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2018/05/News-Release-05-01-2018-1690223023701104.pdf)\n\nApril 25, 2018 \n\n[Pivotal SAKURA Phase 3 Clinical Data to be Featured in Oral and Poster Presentations at The Aesthetic Meeting 2018](/investors/Press-Releases/news-details/2018/Pivotal-SAKURA-Phase-3-Clinical-Data-to-be-Featured-in-Oral-and-Poster-Presentations-at-The-Aesthetic-Meeting-2018-04-25-2018/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2018/Pivotal-SAKURA-Phase-3-Clinical-Data-to-be-Featured-in-Oral-and-Poster-Presentations-at-The-Aesthetic-Meeting-2018-04-25-2018/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2018/04/News-Release-04-25-2018-169022302370133.pdf)\n\nApril 24, 2018 \n\n[Revance Therapeutics to Release First Quarter 2018 Financial Results on Tuesday, May 8, 2018](/investors/Press-Releases/news-details/2018/Revance-Therapeutics-to-Release-First-Quarter-2018-Financial-Results-on-Tuesday-May-8-2018-04-24-2018/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2018/Revance-Therapeutics-to-Release-First-Quarter-2018-Financial-Results-on-Tuesday-May-8-2018-04-24-2018/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2018/04/News-Release-04-24-2018-1690223023701461.pdf)\n\nApril 19, 2018 \n\n[Revance Investor Day Highlights New Neuroscience Indications in Development](/investors/Press-Releases/news-details/2018/Revance-Investor-Day-Highlights-New-Neuroscience-Indications-in-Development-04-19-2018/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2018/Revance-Investor-Day-Highlights-New-Neuroscience-Indications-in-Development-04-19-2018/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2018/04/News-Release-04-19-2018-1690223030485319.pdf)\n\nApril 2, 2018 \n\n[Revance Therapeutics Expands Commercialization Team to Gear Up for Product Launch of RT002 Injectable](/investors/Press-Releases/news-details/2018/Revance-Therapeutics-Expands-Commercialization-Team-to-Gear-Up-for-Product-Launch-of-RT002-Injectable-04-02-2018/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2018/Revance-Therapeutics-Expands-Commercialization-Team-to-Gear-Up-for-Product-Launch-of-RT002-Injectable-04-02-2018/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2018/04/News-Release-04-02-2018-1690223030486682.pdf)\n\nMarch 26, 2018 \n\n[Revance to Host Investor Day on April 19, 2018](/investors/Press-Releases/news-details/2018/Revance-to-Host-Investor-Day-on-April-19-2018-03-26-2018/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2018/Revance-to-Host-Investor-Day-on-April-19-2018-03-26-2018/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2018/03/News-Release-03-26-2018-1690223030486783.pdf)\n\nMarch 20, 2018 \n\n[Revance to Participate in the Needham Healthcare Conference](/investors/Press-Releases/news-details/2018/Revance-to-Participate-in-the-Needham-Healthcare-Conference-03-20-2018/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2018/Revance-to-Participate-in-the-Needham-Healthcare-Conference-03-20-2018/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2018/03/News-Release-03-20-2018-1690223030486990.pdf)\n\nMarch 6, 2018 \n\n[Revance to Participate in Upcoming Investor Conferences](/investors/Press-Releases/news-details/2018/Revance-to-Participate-in-Upcoming-Investor-Conferences-03-06-2018/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2018/Revance-to-Participate-in-Upcoming-Investor-Conferences-03-06-2018/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2018/03/News-Release-03-06-2018-1690223030486488.pdf)\n\nFebruary 28, 2018 \n\n[Mylan to Bring a Biosimilar of BOTOX to the Market Through a Collaboration and License agreement with Revance Therapeutics](/investors/Press-Releases/news-details/2018/Mylan-to-Bring-a-Biosimilar-of-BOTOX-to-the-Market-Through-a-Collaboration-and-License-agreement-with-Revance-Therapeutics-02-28-2018/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2018/Mylan-to-Bring-a-Biosimilar-of-BOTOX-to-the-Market-Through-a-Collaboration-and-License-agreement-with-Revance-Therapeutics-02-28-2018/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2018/02/News-Release-02-22-2018-1690223030486969.pdf)\n\nFebruary 28, 2018 \n\n[Revance Releases Fourth Quarter and Full Year 2017 Results](/investors/Press-Releases/news-details/2018/Revance-Releases-Fourth-Quarter-and-Full-Year-2017-Results-02-28-2018/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2018/Revance-Releases-Fourth-Quarter-and-Full-Year-2017-Results-02-28-2018/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2018/02/News-Release-02-28-2018-169022303048682.pdf)\n\nFebruary 22, 2018 \n\n[Revance Therapeutics to Release Fourth Quarter and Full Year 2017 Financial Results on Wednesday, February 28, 2018](/investors/Press-Releases/news-details/2018/Revance-Therapeutics-to-Release-Fourth-Quarter-and-Full-Year-2017-Financial-Results-on-Wednesday-February-28-2018-02-22-2018/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2018/Revance-Therapeutics-to-Release-Fourth-Quarter-and-Full-Year-2017-Financial-Results-on-Wednesday-February-28-2018-02-22-2018/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2018/02/News-Release-02-22-2018-1690223030486969.pdf)\n\nFebruary 14, 2018 \n\n[Revance to Participate in the RBC Capital Markets 2018 Global Healthcare Conference](/investors/Press-Releases/news-details/2018/Revance-to-Participate-in-the-RBC-Capital-Markets-2018-Global-Healthcare-Conference-02-14-2018/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2018/Revance-to-Participate-in-the-RBC-Capital-Markets-2018-Global-Healthcare-Conference-02-14-2018/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2018/02/News-Release-02-14-2018-1690223030486978.pdf)\n\nFebruary 1, 2018 \n\n[Pivotal SAKURA Phase 3 Clinical Data to be Presented at IMCAS World Congress 2018](/investors/Press-Releases/news-details/2018/Pivotal-SAKURA-Phase-3-Clinical-Data-to-be-Presented-at-IMCAS-World-Congress-2018-02-01-2018/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2018/Pivotal-SAKURA-Phase-3-Clinical-Data-to-be-Presented-at-IMCAS-World-Congress-2018-02-01-2018/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2018/02/News-Release-02-01-2018-1690223030486351.pdf)\n\nJanuary 8, 2018 \n\n[Revance Announces Interim Phase 2a Results for RT002 in Treating Plantar Fasciitis](/investors/Press-Releases/news-details/2018/Revance-Announces-Interim-Phase-2a-Results-for-RT002-in-Treating-Plantar-Fasciitis-01-08-2018/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2018/Revance-Announces-Interim-Phase-2a-Results-for-RT002-in-Treating-Plantar-Fasciitis-01-08-2018/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2018/01/News-Release-01-08-2018-169022303714180.pdf)\n\nJanuary 4, 2018 \n\n[Revance Provides Update on Anticipated Clinical Milestones and Financial Outlook for 2018](/investors/Press-Releases/news-details/2018/Revance-Provides-Update-on-Anticipated-Clinical-Milestones-and-Financial-Outlook-for-2018-01-04-2018/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2018/Revance-Provides-Update-on-Anticipated-Clinical-Milestones-and-Financial-Outlook-for-2018-01-04-2018/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2018/01/News-Release-01-04-2018-1690223037141186.pdf)\n\nDecember 11, 2017 \n\n[Revance Announces Closing of Public Offering of Common Stock](/investors/Press-Releases/news-details/2017/Revance-Announces-Closing-of-Public-Offering-of-Common-Stock-12-11-2017/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2017/Revance-Announces-Closing-of-Public-Offering-of-Common-Stock-12-11-2017/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2017/12/News-Release-12-11-2017-1690223037141634.pdf)\n\nDecember 7, 2017 \n\n[Revance Announces Pricing of Public Offering of Common Stock](/investors/Press-Releases/news-details/2017/Revance-Announces-Pricing-of-Public-Offering-of-Common-Stock-12-07-2017/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2017/Revance-Announces-Pricing-of-Public-Offering-of-Common-Stock-12-07-2017/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2017/12/News-Release-12-07-2017-1690223037141741.pdf)\n\nDecember 5, 2017 \n\n[Revance Announces Proposed Public Offering of Common Stock](/investors/Press-Releases/news-details/2017/Revance-Announces-Proposed-Public-Offering-of-Common-Stock-12-05-2017/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2017/Revance-Announces-Proposed-Public-Offering-of-Common-Stock-12-05-2017/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2017/12/News-Release-12-05-2017-1690223037141928.pdf)\n\nDecember 5, 2017 \n\n[Revance's RT002 Meets Primary and All Secondary Endpoints, Achieves 6-Month Duration in Pivotal SAKURA Phase 3 Trials for Glabellar Lines](/investors/Press-Releases/news-details/2017/Revances-RT002-Meets-Primary-and-All-Secondary-Endpoints-Achieves-6-Month-Duration-in-Pivotal-SAKURA-Phase-3-Trials-for-Glabellar-Lines-12-05-2017/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2017/Revances-RT002-Meets-Primary-and-All-Secondary-Endpoints-Achieves-6-Month-Duration-in-Pivotal-SAKURA-Phase-3-Trials-for-Glabellar-Lines-12-05-2017/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2017/12/News-Release-12-05-2017-1690223037141944.pdf)\n\nNovember 29, 2017 \n\n[Revance Plans Phase 3 Program for RT002 Injectable to Treat Cervical Dystonia](/investors/Press-Releases/news-details/2017/Revance-Plans-Phase-3-Program-for-RT002-Injectable-to-Treat-Cervical-Dystonia-11-29-2017/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2017/Revance-Plans-Phase-3-Program-for-RT002-Injectable-to-Treat-Cervical-Dystonia-11-29-2017/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2017/11/News-Release-11-29-2017-1690223037141488.pdf)\n\nNovember 20, 2017 \n\n[Revance Announces Orphan Drug Designation of RT002 for the Treatment of Cervical Dystonia](/investors/Press-Releases/news-details/2017/Revance-Announces-Orphan-Drug-Designation-of-RT002-for-the-Treatment-of-Cervical-Dystonia-11-20-2017/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2017/Revance-Announces-Orphan-Drug-Designation-of-RT002-for-the-Treatment-of-Cervical-Dystonia-11-20-2017/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2017/11/News-Release-11-20-2017-1690223037141479.pdf)\n\nNovember 2, 2017 \n\n[Revance Releases Third Quarter 2017 Results](/investors/Press-Releases/news-details/2017/Revance-Releases-Third-Quarter-2017-Results-11-02-2017/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2017/Revance-Releases-Third-Quarter-2017-Results-11-02-2017/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2017/11/News-Release-11-02-2017-1690223037141495.pdf)\n\nOctober 18, 2017 \n\n[Revance Therapeutics to Release Third Quarter 2017 Financial Results Thursday, November 2, 2017](/investors/Press-Releases/news-details/2017/Revance-Therapeutics-to-Release-Third-Quarter-2017-Financial-Results-Thursday-November-2-2017-10-18-2017/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2017/Revance-Therapeutics-to-Release-Third-Quarter-2017-Financial-Results-Thursday-November-2-2017-10-18-2017/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2017/10/News-Release-10-18-2017-1690223037141838.pdf)\n\nOctober 18, 2017 \n\n[Revance Completes Patient Enrollment in Phase 2 Program for RT002 Injectable in the Management of Plantar Fasciitis](/investors/Press-Releases/news-details/2017/Revance-Completes-Patient-Enrollment-in-Phase-2-Program-for-RT002-Injectable-in-the-Management-of-Plantar-Fasciitis-10-18-2017/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2017/Revance-Completes-Patient-Enrollment-in-Phase-2-Program-for-RT002-Injectable-in-the-Management-of-Plantar-Fasciitis-10-18-2017/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2017/10/News-Release-10-18-2017-1690223043898965.pdf)\n\nSeptember 19, 2017 \n\n[Revance to Participate in the Cantor Fitzgerald 2017 Global Healthcare Conference](/investors/Press-Releases/news-details/2017/Revance-to-Participate-in-the-Cantor-Fitzgerald-2017-Global-Healthcare-Conference-09-19-2017/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2017/Revance-to-Participate-in-the-Cantor-Fitzgerald-2017-Global-Healthcare-Conference-09-19-2017/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2017/09/News-Release-09-19-2017-1690223043898940.pdf)\n\nSeptember 6, 2017 \n\n[Revance Appoints Mark Foley to its Board of Directors](/investors/Press-Releases/news-details/2017/Revance-Appoints-Mark-Foley-to-its-Board-of-Directors-09-06-2017/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2017/Revance-Appoints-Mark-Foley-to-its-Board-of-Directors-09-06-2017/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2017/09/News-Release-09-06-2017-1690223043898613.pdf)\n\nAugust 30, 2017 \n\n[Revance to Participate in the 2017 Wells Fargo Securities Healthcare Conference](/investors/Press-Releases/news-details/2017/Revance-to-Participate-in-the-2017-Wells-Fargo-Securities-Healthcare-Conference-08-30-2017/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2017/Revance-to-Participate-in-the-2017-Wells-Fargo-Securities-Healthcare-Conference-08-30-2017/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2017/08/News-Release-08-30-2017-1690223043898615.pdf)\n\nAugust 3, 2017 \n\n[Revance Releases Second Quarter 2017 Results](/investors/Press-Releases/news-details/2017/Revance-Releases-Second-Quarter-2017-Results-08-03-2017/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2017/Revance-Releases-Second-Quarter-2017-Results-08-03-2017/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2017/08/News-Release-08-03-2017-1690223043898615.pdf)\n\nAugust 2, 2017 \n\n[Revance Therapeutics Expands Leadership Team, Appointing Todd Zavodnick Chief Commercial Officer and President, Aesthetics & Therapeutics](/investors/Press-Releases/news-details/2017/Revance-Therapeutics-Expands-Leadership-Team-Appointing-Todd-Zavodnick-Chief-Commercial-Officer-and-President-Aesthetics-Therapeutics-08-02-2017/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2017/Revance-Therapeutics-Expands-Leadership-Team-Appointing-Todd-Zavodnick-Chief-Commercial-Officer-and-President-Aesthetics-Therapeutics-08-02-2017/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2017/08/News-Release-08-02-2017-1690223043898767.pdf)\n\nJuly 24, 2017 \n\n[Revance Therapeutics to Release Second Quarter 2017 Financial Results Thursday, August 3, 2017](/investors/Press-Releases/news-details/2017/Revance-Therapeutics-to-Release-Second-Quarter-2017-Financial-Results-Thursday-August-3-2017-07-24-2017/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2017/Revance-Therapeutics-to-Release-Second-Quarter-2017-Financial-Results-Thursday-August-3-2017-07-24-2017/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2017/07/News-Release-07-24-2017-1690223043898835.pdf)\n\nJune 15, 2017 \n\n[Positive BELMONT Phase 2 Trial Results Published in Dermatologic Surgery](/investors/Press-Releases/news-details/2017/Positive-BELMONT-Phase-2-Trial-Results-Published-in-Dermatologic-Surgery-06-15-2017/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2017/Positive-BELMONT-Phase-2-Trial-Results-Published-in-Dermatologic-Surgery-06-15-2017/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2017/06/News-Release-06-15-2017-1690223043898532.pdf)\n\nJune 5, 2017 \n\n[Revance Reports Additional Positive Week 24 Efficacy Results from RT002 Injectable Phase 2 Cervical Dystonia Trial](/investors/Press-Releases/news-details/2017/Revance-Reports-Additional-Positive-Week-24-Efficacy-Results-from-RT002-Injectable-Phase-2-Cervical-Dystonia-Trial-06-05-2017/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2017/Revance-Reports-Additional-Positive-Week-24-Efficacy-Results-from-RT002-Injectable-Phase-2-Cervical-Dystonia-Trial-06-05-2017/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2017/06/News-Release-06-05-2017-1690223043898898.pdf)\n\nJune 1, 2017 \n\n[Revance to Participate in Upcoming Investor Conferences](/investors/Press-Releases/news-details/2017/Revance-to-Participate-in-Upcoming-Investor-Conferences-06-01-2017/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2017/Revance-to-Participate-in-Upcoming-Investor-Conferences-06-01-2017/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2017/06/News-Release-06-01-2017-1690223043898736.pdf)\n\nMay 18, 2017 \n\n[Revance Announces Positive Top-Line 24-Week Duration of Effect Results in All Three Cohorts in RT002 Injectable Phase 2 Cervical Dystonia Trial](/investors/Press-Releases/news-details/2017/Revance-Announces-Positive-Top-Line-24-Week-Duration-of-Effect-Results-in-All-Three-Cohorts-in-RT002-Injectable-Phase-2-Cervical-Dystonia-Trial-05-18-2017/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2017/Revance-Announces-Positive-Top-Line-24-Week-Duration-of-Effect-Results-in-All-Three-Cohorts-in-RT002-Injectable-Phase-2-Cervical-Dystonia-Trial-05-18-2017/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2017/05/News-Release-05-18-2017-169022305077212.pdf)\n\nMay 9, 2017 \n\n[Revance Releases First Quarter 2017 Results](/investors/Press-Releases/news-details/2017/Revance-Releases-First-Quarter-2017-Results-05-09-2017/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2017/Revance-Releases-First-Quarter-2017-Results-05-09-2017/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2017/05/News-Release-05-09-2017-1690223050772747.pdf)\n\nMay 1, 2017 \n\n[Revance Provides Update on Phase 2 Program for RT002 Injectable in the Management of Plantar Fasciitis](/investors/Press-Releases/news-details/2017/Revance-Provides-Update-on-Phase-2-Program-for-RT002-Injectable-in-the-Management-of-Plantar-Fasciitis-05-01-2017/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2017/Revance-Provides-Update-on-Phase-2-Program-for-RT002-Injectable-in-the-Management-of-Plantar-Fasciitis-05-01-2017/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2017/05/News-Release-05-01-2017-1690223050772118.pdf)\n\nApril 25, 2017 \n\n[Revance Therapeutics to Release First Quarter 2017 Financial Results Tuesday, May 9, 2017](/investors/Press-Releases/news-details/2017/Revance-Therapeutics-to-Release-First-Quarter-2017-Financial-Results-Tuesday-May-9-2017-04-25-2017/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2017/Revance-Therapeutics-to-Release-First-Quarter-2017-Financial-Results-Tuesday-May-9-2017-04-25-2017/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2017/04/News-Release-04-25-2017-169022305077259.pdf)\n\nMarch 7, 2017 \n\n[Revance Completes Enrollment in Phase 3 Pivotal Trials of RT002 Injectable for the Treatment of Glabellar (Frown) Lines](/investors/Press-Releases/news-details/2017/Revance-Completes-Enrollment-in-Phase-3-Pivotal-Trials-of-RT002-Injectable-for-the-Treatment-of-Glabellar-Frown-Lines-03-07-2017/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2017/Revance-Completes-Enrollment-in-Phase-3-Pivotal-Trials-of-RT002-Injectable-for-the-Treatment-of-Glabellar-Frown-Lines-03-07-2017/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2017/03/News-Release-03-07-2017-1690223050773242.pdf)\n\nMarch 3, 2017 \n\n[Revance Announces BELMONT Phase 2 Clinical Data to Be Presented at the 2017 American Academy of Dermatology (AAD) Annual Meeting](/investors/Press-Releases/news-details/2017/Revance-Announces-BELMONT-Phase-2-Clinical-Data-to-Be-Presented-at-the-2017-American-Academy-of-Dermatology-AAD-Annual-Meeting-03-03-2017/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2017/Revance-Announces-BELMONT-Phase-2-Clinical-Data-to-Be-Presented-at-the-2017-American-Academy-of-Dermatology-AAD-Annual-Meeting-03-03-2017/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2017/03/News-Release-03-03-2017-1690223050773262.pdf)\n\nFebruary 27, 2017 \n\n[Revance Releases Fourth Quarter and Full Year 2016 Results](/investors/Press-Releases/news-details/2017/Revance-Releases-Fourth-Quarter-and-Full-Year-2016-Results-02-27-2017/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2017/Revance-Releases-Fourth-Quarter-and-Full-Year-2016-Results-02-27-2017/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2017/02/News-Release-02-27-2017-1690223050773481.pdf)\n\nFebruary 22, 2017 \n\n[Revance to Participate in Upcoming Investor Conferences](/investors/Press-Releases/news-details/2017/Revance-to-Participate-in-Upcoming-Investor-Conferences-02-22-2017/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2017/Revance-to-Participate-in-Upcoming-Investor-Conferences-02-22-2017/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2017/02/News-Release-02-22-2017-169022305077366.pdf)\n\nFebruary 16, 2017 \n\n[Revance Therapeutics to Release Fourth Quarter 2016 Financial Results Monday, February 27, 2017](/investors/Press-Releases/news-details/2017/Revance-Therapeutics-to-Release-Fourth-Quarter-2016-Financial-Results-Monday-February-27-2017-02-16-2017/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2017/Revance-Therapeutics-to-Release-Fourth-Quarter-2016-Financial-Results-Monday-February-27-2017-02-16-2017/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2017/02/News-Release-02-16-2017-1690223050773825.pdf)\n\nJanuary 26, 2017 \n\n[BELMONT Phase 2 Clinical Data to be Presented at IMCAS World Congress 2017](/investors/Press-Releases/news-details/2017/BELMONT-Phase-2-Clinical-Data-to-be-Presented-at-IMCAS-World-Congress-2017-01-26-2017/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2017/BELMONT-Phase-2-Clinical-Data-to-be-Presented-at-IMCAS-World-Congress-2017-01-26-2017/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2017/01/News-Release-01-26-2017-16902230507734.pdf)\n\nJanuary 18, 2017 \n\n[Revance Presents Clinical Data for RT002 Injectable at TOXINS 2017](/investors/Press-Releases/news-details/2017/Revance-Presents-Clinical-Data-for-RT002-Injectable-at-TOXINS-2017-01-18-2017/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2017/Revance-Presents-Clinical-Data-for-RT002-Injectable-at-TOXINS-2017-01-18-2017/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2017/01/News-Release-01-18-2017-169022305751554.pdf)\n\nJanuary 5, 2017 \n\n[Revance Provides Clinical Milestones and Financial Outlook for 2017](/investors/Press-Releases/news-details/2017/Revance-Provides-Clinical-Milestones-and-Financial-Outlook-for-2017-01-05-2017/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2017/Revance-Provides-Clinical-Milestones-and-Financial-Outlook-for-2017-01-05-2017/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2017/01/News-Release-01-05-2017-1690223057515413.pdf)\n\nDecember 12, 2016 \n\n[Revance Announces Positive 24-Week Duration of Effect in Interim Results from Phase 2 Cervical Dystonia Trial](/investors/Press-Releases/news-details/2016/Revance-Announces-Positive-24-Week-Duration-of-Effect-in-Interim-Results-from-Phase-2-Cervical-Dystonia-Trial-12-12-2016/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2016/Revance-Announces-Positive-24-Week-Duration-of-Effect-in-Interim-Results-from-Phase-2-Cervical-Dystonia-Trial-12-12-2016/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2016/12/News-Release-12-12-2016-1690223057515633.pdf)\n\nDecember 7, 2016 \n\n[Revance Announces Initiation of Subject Dosing in the SAKURA Phase 3 Clinical Program of RT002 Injectable for the Treatment of Glabellar (Frown) Lines](/investors/Press-Releases/news-details/2016/Revance-Announces-Initiation-of-Subject-Dosing-in-the-SAKURA-Phase-3-Clinical-Program-of-RT002-Injectable-for-the-Treatment-of-Glabellar-Frown-Lines-12-07-2016/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2016/Revance-Announces-Initiation-of-Subject-Dosing-in-the-SAKURA-Phase-3-Clinical-Program-of-RT002-Injectable-for-the-Treatment-of-Glabellar-Frown-Lines-12-07-2016/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2016/12/News-Release-12-07-2016-1690223057515317.pdf)\n\nNovember 17, 2016 \n\n[Revance to Participate in the 28th Annual Piper Jaffray Healthcare Conference](/investors/Press-Releases/news-details/2016/Revance-to-Participate-in-the-28th-Annual-Piper-Jaffray-Healthcare-Conference-11-17-2016/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2016/Revance-to-Participate-in-the-28th-Annual-Piper-Jaffray-Healthcare-Conference-11-17-2016/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2016/11/News-Release-11-17-2016-169022305751595.pdf)\n\nNovember 7, 2016 \n\n[Revance to Participate in the Jefferies 2016 London Healthcare Conference](/investors/Press-Releases/news-details/2016/Revance-to-Participate-in-the-Jefferies-2016-London-Healthcare-Conference-11-07-2016/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2016/Revance-to-Participate-in-the-Jefferies-2016-London-Healthcare-Conference-11-07-2016/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2016/11/News-Release-11-07-2016-1690223057515264.pdf)\n\nNovember 3, 2016 \n\n[Revance Announces Initiation of Phase 2 Trial of RT002 Injectable to Treat Plantar Fasciitis](/investors/Press-Releases/news-details/2016/Revance-Announces-Initiation-of-Phase-2-Trial-of-RT002-Injectable-to-Treat-Plantar-Fasciitis-11-03-2016/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2016/Revance-Announces-Initiation-of-Phase-2-Trial-of-RT002-Injectable-to-Treat-Plantar-Fasciitis-11-03-2016/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2016/11/News-Release-11-03-2016-1690223057515135.pdf)\n\nNovember 3, 2016 \n\n[Revance Releases Third Quarter 2016 Results](/investors/Press-Releases/news-details/2016/Revance-Releases-Third-Quarter-2016-Results-11-03-2016/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2016/Revance-Releases-Third-Quarter-2016-Results-11-03-2016/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2016/11/News-Release-11-03-2016-1690223057515799.pdf)\n\nOctober 24, 2016 \n\n[Revance Therapeutics to Release Third Quarter 2016 Financial Results Thursday, November 3, 2016](/investors/Press-Releases/news-details/2016/Revance-Therapeutics-to-Release-Third-Quarter-2016-Financial-Results-Thursday-November-3-2016-10-24-2016/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2016/Revance-Therapeutics-to-Release-Third-Quarter-2016-Financial-Results-Thursday-November-3-2016-10-24-2016/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2016/10/News-Release-10-24-2016-1690223057515723.pdf)\n\nAugust 30, 2016 \n\n[Revance to Participate in the 2016 Wells Fargo Securities Healthcare Conference](/investors/Press-Releases/news-details/2016/Revance-to-Participate-in-the-2016-Wells-Fargo-Securities-Healthcare-Conference-08-30-2016/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2016/Revance-to-Participate-in-the-2016-Wells-Fargo-Securities-Healthcare-Conference-08-30-2016/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2016/08/News-Release-08-30-2016-1690223057515997.pdf)\n\nAugust 4, 2016 \n\n[Revance Releases Second Quarter 2016 Results](/investors/Press-Releases/news-details/2016/Revance-Releases-Second-Quarter-2016-Results-08-04-2016/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2016/Revance-Releases-Second-Quarter-2016-Results-08-04-2016/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2016/08/News-Release-08-04-2016-1690223064286269.pdf)\n\nJuly 21, 2016 \n\n[Revance Therapeutics to Release Second Quarter 2016 Financial Results Thursday, August 4, 2016](/investors/Press-Releases/news-details/2016/Revance-Therapeutics-to-Release-Second-Quarter-2016-Financial-Results-Thursday-August-4-2016-07-21-2016/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2016/Revance-Therapeutics-to-Release-Second-Quarter-2016-Financial-Results-Thursday-August-4-2016-07-21-2016/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2016/07/News-Release-07-21-2016-1690223064287928.pdf)\n\nJuly 14, 2016 \n\n[Revance Announces Completion of Pre-Phase 3 Meeting with FDA for RT002 Injectable to Treat Glabellar Lines](/investors/Press-Releases/news-details/2016/Revance-Announces-Completion-of-Pre-Phase-3-Meeting-with-FDA-for-RT002-Injectable-to-Treat-Glabellar-Lines-07-14-2016/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2016/Revance-Announces-Completion-of-Pre-Phase-3-Meeting-with-FDA-for-RT002-Injectable-to-Treat-Glabellar-Lines-07-14-2016/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2016/07/News-Release-07-14-2016-1690223064287323.pdf)\n\nJuly 5, 2016 \n\n[Revance Appoints Industry Leader Julian S. Gangolli to its Board of Directors](/investors/Press-Releases/news-details/2016/Revance-Appoints-Industry-Leader-Julian-S.-Gangolli-to-its-Board-of-Directors-07-05-2016/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2016/Revance-Appoints-Industry-Leader-Julian-S.-Gangolli-to-its-Board-of-Directors-07-05-2016/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2016/07/News-Release-07-05-2016-1690223064287649.pdf)\n\nJune 13, 2016 \n\n[Revance Reports Results for RT001 Topical Phase 3 Trial for Lateral Canthal Lines](/investors/Press-Releases/news-details/2016/Revance-Reports-Results-for-RT001-Topical-Phase-3-Trial-for-Lateral-Canthal-Lines-06-13-2016/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2016/Revance-Reports-Results-for-RT001-Topical-Phase-3-Trial-for-Lateral-Canthal-Lines-06-13-2016/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2016/06/News-Release-06-13-2016-169022306428751.pdf)\n\nJune 2, 2016 \n\n[Revance Expands Botulinum Toxin Assets by Acquiring Intellectual Property (IP) Portfolio](/investors/Press-Releases/news-details/2016/Revance-Expands-Botulinum-Toxin-Assets-by-Acquiring-Intellectual-Property-IP-Portfolio-06-02-2016/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2016/Revance-Expands-Botulinum-Toxin-Assets-by-Acquiring-Intellectual-Property-IP-Portfolio-06-02-2016/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2016/06/News-Release-06-02-2016-1690223064287698.pdf)\n\nMay 31, 2016 \n\n[Revance to Participate in Upcoming Investor Conferences](/investors/Press-Releases/news-details/2016/Revance-to-Participate-in-Upcoming-Investor-Conferences-05-31-2016/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2016/Revance-to-Participate-in-Upcoming-Investor-Conferences-05-31-2016/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2016/05/News-Release-05-31-2016-1690223064287612.pdf)\n\nMay 9, 2016 \n\n[Revance Releases First Quarter 2016 Results](/investors/Press-Releases/news-details/2016/Revance-Releases-First-Quarter-2016-Results-05-09-2016/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2016/Revance-Releases-First-Quarter-2016-Results-05-09-2016/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2016/05/News-Release-05-09-2016-1690223064287932.pdf)\n\nApril 25, 2016 \n\n[Revance Therapeutics to Release First Quarter 2016 Financial Results Monday, May 9, 2016](/investors/Press-Releases/news-details/2016/Revance-Therapeutics-to-Release-First-Quarter-2016-Financial-Results-Monday-May-9-2016-04-25-2016/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2016/Revance-Therapeutics-to-Release-First-Quarter-2016-Financial-Results-Monday-May-9-2016-04-25-2016/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2016/04/News-Release-04-25-2016-1690223064287867.pdf)\n\nApril 4, 2016 \n\n[Abhay Joshi, PhD, MBA, Chief Operating Officer of Revance, Honored by the American Institute for Medical and Biological Engineering (AIMBE)](/investors/Press-Releases/news-details/2016/Abhay-Joshi-PhD-MBA-Chief-Operating-Officer-of-Revance-Honored-by-the-American-Institute-for-Medical-and-Biological-Engineering-AIMBE-04-04-2016/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2016/Abhay-Joshi-PhD-MBA-Chief-Operating-Officer-of-Revance-Honored-by-the-American-Institute-for-Medical-and-Biological-Engineering-AIMBE-04-04-2016/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2016/04/News-Release-04-04-2016-1690223064287500.pdf)\n\nMarch 14, 2016 \n\n[Revance Therapeutics Expands Leadership Team, Appoints Roman G. Rubio, MD, MBA, as Senior Vice President of Clinical Development](/investors/Press-Releases/news-details/2016/Revance-Therapeutics-Expands-Leadership-Team-Appoints-Roman-G.-Rubio-MD-MBA-as-Senior-Vice-President-of-Clinical-Development-03-14-2016/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2016/Revance-Therapeutics-Expands-Leadership-Team-Appoints-Roman-G.-Rubio-MD-MBA-as-Senior-Vice-President-of-Clinical-Development-03-14-2016/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2016/03/News-Release-03-14-2016-169022307104538.pdf)\n\nMarch 5, 2016 \n\n[Revance Announces Late-Breaking Podium Presentation of Positive 6-Month Duration Results for BELMONT Phase 2 Active Comparator Study of Injectable RT002 at the 74th Annual Meeting of the American Academy of Dermatology](/investors/Press-Releases/news-details/2016/Revance-Announces-Late-Breaking-Podium-Presentation-of-Positive-6-Month-Duration-Results-for-BELMONT-Phase-2-Active-Comparator-Study-of-Injectable-RT002-at-the-74th-Annual-Meeting-of-the-American-Academy-of-Dermatology-03-05-2016/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2016/Revance-Announces-Late-Breaking-Podium-Presentation-of-Positive-6-Month-Duration-Results-for-BELMONT-Phase-2-Active-Comparator-Study-of-Injectable-RT002-at-the-74th-Annual-Meeting-of-the-American-Academy-of-Dermatology-03-05-2016/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2016/03/News-Release-03-05-2016-1690223071046290.pdf)\n\nMarch 2, 2016 \n\n[Revance Releases Fourth Quarter and Full Year 2015 Results](/investors/Press-Releases/news-details/2016/Revance-Releases-Fourth-Quarter-and-Full-Year-2015-Results-03-02-2016/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2016/Revance-Releases-Fourth-Quarter-and-Full-Year-2015-Results-03-02-2016/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2016/03/News-Release-03-02-2016-1690223071046798.pdf)\n\nFebruary 23, 2016 \n\n[Revance to Participate in Upcoming Investor Conferences](/investors/Press-Releases/news-details/2016/Revance-to-Participate-in-Upcoming-Investor-Conferences-02-23-2016/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2016/Revance-to-Participate-in-Upcoming-Investor-Conferences-02-23-2016/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2016/02/News-Release-02-23-2016-1690223071046514.pdf)\n\nFebruary 17, 2016 \n\n[Revance Therapeutics to Release Fourth Quarter and Full Year 2015 Financial Results Wednesday, March 2, 2016](/investors/Press-Releases/news-details/2016/Revance-Therapeutics-to-Release-Fourth-Quarter-and-Full-Year-2015-Financial-Results-Wednesday-March-2-2016-02-17-2016/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2016/Revance-Therapeutics-to-Release-Fourth-Quarter-and-Full-Year-2015-Financial-Results-Wednesday-March-2-2016-02-17-2016/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2016/02/News-Release-02-17-2016-1690223071046583.pdf)\n\nJanuary 7, 2016 \n\n[Revance Specifies 2016 Clinical Program Milestones](/investors/Press-Releases/news-details/2016/Revance-Specifies-2016-Clinical-Program-Milestones-01-07-2016/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2016/Revance-Specifies-2016-Clinical-Program-Milestones-01-07-2016/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2016/01/News-Release-01-07-2016-1690223071046781.pdf)\n\nDecember 23, 2015 \n\n[Revance Announces Positive Phase 2 Results for RT001 Botulinum Toxin Type A Topical Gel to Treat Axillary Hyperhidrosis](/investors/Press-Releases/news-details/2015/Revance-Announces-Positive-Phase-2-Results-for-RT001-Botulinum-Toxin-Type-A-Topical-Gel-to-Treat-Axillary-Hyperhidrosis-12-23-2015/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2015/Revance-Announces-Positive-Phase-2-Results-for-RT001-Botulinum-Toxin-Type-A-Topical-Gel-to-Treat-Axillary-Hyperhidrosis-12-23-2015/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2015/12/News-Release-12-23-2015-1690223071046568.pdf)\n\nDecember 14, 2015 \n\n[Revance Appoints Abhay Joshi, PhD, as Chief Operating Officer](/investors/Press-Releases/news-details/2015/Revance-Appoints-Abhay-Joshi-PhD-as-Chief-Operating-Officer-12-14-2015/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2015/Revance-Appoints-Abhay-Joshi-PhD-as-Chief-Operating-Officer-12-14-2015/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2015/12/News-Release-12-14-2015-1690223071046496.pdf)\n\nNovember 19, 2015 \n\n[Revance Therapeutics to Participate in the 27th Annual Piper Jaffray Healthcare Conference](/investors/Press-Releases/news-details/2015/Revance-Therapeutics-to-Participate-in-the-27th-Annual-Piper-Jaffray-Healthcare-Conference-11-19-2015/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2015/Revance-Therapeutics-to-Participate-in-the-27th-Annual-Piper-Jaffray-Healthcare-Conference-11-19-2015/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2015/11/News-Release-11-19-2015-1690223071046262.pdf)\n\nNovember 9, 2015 \n\n[Revance Therapeutics Announces Closing of Public Offering of Common Stock](/investors/Press-Releases/news-details/2015/Revance-Therapeutics-Announces-Closing-of-Public-Offering-of-Common-Stock-11-09-2015/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2015/Revance-Therapeutics-Announces-Closing-of-Public-Offering-of-Common-Stock-11-09-2015/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2015/11/News-Release-11-09-2015-1690223077759481.pdf)\n\nNovember 9, 2015 \n\n[Revance Therapeutics Releases Third Quarter 2015 Results](/investors/Press-Releases/news-details/2015/Revance-Therapeutics-Releases-Third-Quarter-2015-Results-11-09-2015/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2015/Revance-Therapeutics-Releases-Third-Quarter-2015-Results-11-09-2015/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2015/11/News-Release-11-09-2015-1690223071046804.pdf)\n\nNovember 4, 2015 \n\n[Revance Therapeutics to Present at Credit Suisse 24th Annual Healthcare Conference](/investors/Press-Releases/news-details/2015/Revance-Therapeutics-to-Present-at-Credit-Suisse-24th-Annual-Healthcare-Conference-11-04-2015/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2015/Revance-Therapeutics-to-Present-at-Credit-Suisse-24th-Annual-Healthcare-Conference-11-04-2015/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2015/11/News-Release-11-04-2015-1690223077759645.pdf)\n\nNovember 4, 2015 \n\n[Revance Therapeutics to Release Third Quarter 2015 Financial Results Monday, November 9, 2015](/investors/Press-Releases/news-details/2015/Revance-Therapeutics-to-Release-Third-Quarter-2015-Financial-Results-Monday-November-9-2015-11-04-2015/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2015/Revance-Therapeutics-to-Release-Third-Quarter-2015-Financial-Results-Monday-November-9-2015-11-04-2015/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2015/11/News-Release-11-04-2015-1690223077759973.pdf)\n\nNovember 4, 2015 \n\n[Revance Therapeutics Announces Pricing of Public Offering of Common Stock](/investors/Press-Releases/news-details/2015/Revance-Therapeutics-Announces-Pricing-of-Public-Offering-of-Common-Stock-11-04-2015/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2015/Revance-Therapeutics-Announces-Pricing-of-Public-Offering-of-Common-Stock-11-04-2015/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2015/11/News-Release-11-04-2015-1690223077759329.pdf)\n\nNovember 2, 2015 \n\n[Revance Therapeutics Announces Proposed Public Offering of Common Stock](/investors/Press-Releases/news-details/2015/Revance-Therapeutics-Announces-Proposed-Public-Offering-of-Common-Stock-11-02-2015/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2015/Revance-Therapeutics-Announces-Proposed-Public-Offering-of-Common-Stock-11-02-2015/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2015/11/News-Release-11-02-2015-1690223077759292.pdf)\n\nOctober 29, 2015 \n\n[Revance Reports Positive 6-Month Duration in BELMONT Study](/investors/Press-Releases/news-details/2015/Revance-Reports-Positive-6-Month-Duration-in-BELMONT-Study-10-29-2015/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2015/Revance-Reports-Positive-6-Month-Duration-in-BELMONT-Study-10-29-2015/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2015/10/News-Release-10-29-2015-1690223077759168.pdf)\n\nSeptember 29, 2015 \n\n[Revance Therapeutics Initiates Phase 2 Clinical Study of Its Unique Botulinum Toxin Type A for Injection to Treat Cervical Dystonia](/investors/Press-Releases/news-details/2015/Revance-Therapeutics-Initiates-Phase-2-Clinical-Study-of-Its-Unique-Botulinum-Toxin-Type-A-for-Injection-to-Treat-Cervical-Dystonia-09-29-2015/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2015/Revance-Therapeutics-Initiates-Phase-2-Clinical-Study-of-Its-Unique-Botulinum-Toxin-Type-A-for-Injection-to-Treat-Cervical-Dystonia-09-29-2015/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2015/09/News-Release-09-29-2015-1690223077759920.pdf)\n\nSeptember 28, 2015 \n\n[Revance Therapeutics Initiates Phase 3 Clinical Trial of Botulinum Toxin Type A Topical Gel to Treat Lateral Canthal Lines](/investors/Press-Releases/news-details/2015/Revance-Therapeutics-Initiates-Phase-3-Clinical-Trial-of-Botulinum-Toxin-Type-A-Topical-Gel-to-Treat-Lateral-Canthal-Lines-09-28-2015/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2015/Revance-Therapeutics-Initiates-Phase-3-Clinical-Trial-of-Botulinum-Toxin-Type-A-Topical-Gel-to-Treat-Lateral-Canthal-Lines-09-28-2015/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2015/09/News-Release-09-28-2015-1690223077760835.pdf)\n\nSeptember 9, 2015 \n\n[Revance Therapeutics Initiates Phase 2 Clinical Trial of Botulinum Toxin Type A Topical Gel to Treat Axillary Hyperhidrosis](/investors/Press-Releases/news-details/2015/Revance-Therapeutics-Initiates-Phase-2-Clinical-Trial-of-Botulinum-Toxin-Type-A-Topical-Gel-to-Treat-Axillary-Hyperhidrosis-09-09-2015/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2015/Revance-Therapeutics-Initiates-Phase-2-Clinical-Trial-of-Botulinum-Toxin-Type-A-Topical-Gel-to-Treat-Axillary-Hyperhidrosis-09-09-2015/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2015/09/News-Release-09-09-2015-1690223077760734.pdf)\n\nAugust 6, 2015 \n\n[Revance Therapeutics Releases Second Quarter 2015 Results](/investors/Press-Releases/news-details/2015/Revance-Therapeutics-Releases-Second-Quarter-2015-Results-08-06-2015/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2015/Revance-Therapeutics-Releases-Second-Quarter-2015-Results-08-06-2015/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2015/08/News-Release-08-06-2015-1690223077760890.pdf)\n\nJuly 23, 2015 \n\n[Revance Therapeutics to Release Second Quarter 2015 Financial Results Thursday, August 6, 2015](/investors/Press-Releases/news-details/2015/Revance-Therapeutics-to-Release-Second-Quarter-2015-Financial-Results-Thursday-August-6-2015-07-23-2015/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2015/Revance-Therapeutics-to-Release-Second-Quarter-2015-Financial-Results-Thursday-August-6-2015-07-23-2015/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2015/07/News-Release-07-23-2015-1690223084439224.pdf)\n\nJuly 2, 2015 \n\n[Revance Therapeutics Announces Change in Role of Jacob Waugh, M.D.](/investors/Press-Releases/news-details/2015/Revance-Therapeutics-Announces-Change-in-Role-of-Jacob-Waugh-M.D.-07-02-2015/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2015/Revance-Therapeutics-Announces-Change-in-Role-of-Jacob-Waugh-M.D.-07-02-2015/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2015/07/News-Release-07-02-2015-1690223084439945.pdf)\n\nJune 3, 2015 \n\n[Revance Therapeutics to Initiate Two Key Trials for RT001, Its Topical Botulinum Toxin Type A Investigational Drug Product Candidate](/investors/Press-Releases/news-details/2015/Revance-Therapeutics-to-Initiate-Two-Key-Trials-for-RT001-Its-Topical-Botulinum-Toxin-Type-A-Investigational-Drug-Product-Candidate-06-03-2015/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2015/Revance-Therapeutics-to-Initiate-Two-Key-Trials-for-RT001-Its-Topical-Botulinum-Toxin-Type-A-Investigational-Drug-Product-Candidate-06-03-2015/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2015/06/News-Release-06-03-2015-1690223084439766.pdf)\n\nMay 21, 2015 \n\n[Revance to Participate in Upcoming Investor Conferences](/investors/Press-Releases/news-details/2015/Revance-to-Participate-in-Upcoming-Investor-Conferences-05-21-2015/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2015/Revance-to-Participate-in-Upcoming-Investor-Conferences-05-21-2015/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2015/05/News-Release-05-21-2015-1690223084439239.pdf)\n\nMay 13, 2015 \n\n[Revance Therapeutics Releases First Quarter 2015 Financial Results](/investors/Press-Releases/news-details/2015/Revance-Therapeutics-Releases-First-Quarter-2015-Financial-Results-05-13-2015/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2015/Revance-Therapeutics-Releases-First-Quarter-2015-Financial-Results-05-13-2015/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2015/05/News-Release-05-13-2015-1690223084439148.pdf)\n\nApril 29, 2015 \n\n[Revance Therapeutics to Release First Quarter 2015 Financial Results Wednesday, May 13, 2015](/investors/Press-Releases/news-details/2015/Revance-Therapeutics-to-Release-First-Quarter-2015-Financial-Results-Wednesday-May-13-2015-04-29-2015/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2015/Revance-Therapeutics-to-Release-First-Quarter-2015-Financial-Results-Wednesday-May-13-2015-04-29-2015/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2015/04/News-Release-04-29-2015-1690223084439884.pdf)\n\nMarch 2, 2015 \n\n[Revance Therapeutics Releases Fourth Quarter and Full Year 2014 Financial Results and Reiterates 2015 Outlook](/investors/Press-Releases/news-details/2015/Revance-Therapeutics-Releases-Fourth-Quarter-and-Full-Year-2014-Financial-Results-and-Reiterates-2015-Outlook-03-02-2015/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2015/Revance-Therapeutics-Releases-Fourth-Quarter-and-Full-Year-2014-Financial-Results-and-Reiterates-2015-Outlook-03-02-2015/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2015/03/News-Release-03-02-2015-1690223084439855.pdf)\n\nFebruary 26, 2015 \n\n[Revance Appoints Dr. Philip Vickers to Its Board of Directors](/investors/Press-Releases/news-details/2015/Revance-Appoints-Dr.-Philip-Vickers-to-Its-Board-of-Directors-02-26-2015/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2015/Revance-Appoints-Dr.-Philip-Vickers-to-Its-Board-of-Directors-02-26-2015/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2015/02/News-Release-02-26-2015-1690223084439645.pdf)\n\nFebruary 17, 2015 \n\n[Revance Therapeutics, Inc. Announces Participation in Cowen 35th Annual Health Care Conference](/investors/Press-Releases/news-details/2015/Revance-Therapeutics-Inc.-Announces-Participation-in-Cowen-35th-Annual-Health-Care-Conference-02-17-2015/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2015/Revance-Therapeutics-Inc.-Announces-Participation-in-Cowen-35th-Annual-Health-Care-Conference-02-17-2015/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2015/02/News-Release-02-17-2015-1690223084439881.pdf)\n\nFebruary 12, 2015 \n\n[Revance Therapeutics to Release Fourth Quarter and Full Year 2014 Financial Results and Host Conference Call on Monday, March 2, 2015](/investors/Press-Releases/news-details/2015/Revance-Therapeutics-to-Release-Fourth-Quarter-and-Full-Year-2014-Financial-Results-and-Host-Conference-Call-on-Monday-March-2-2015-02-12-2015/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2015/Revance-Therapeutics-to-Release-Fourth-Quarter-and-Full-Year-2014-Financial-Results-and-Host-Conference-Call-on-Monday-March-2-2015-02-12-2015/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2015/02/News-Release-02-12-2015-1690223084439385.pdf)\n\nJanuary 12, 2015 \n\n[Revance Therapeutics Defines Clinical Program Milestones and Provides Financial Guidance for 2015](/investors/Press-Releases/news-details/2015/Revance-Therapeutics-Defines-Clinical-Program-Milestones-and-Provides-Financial-Guidance-for-2015-01-12-2015/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2015/Revance-Therapeutics-Defines-Clinical-Program-Milestones-and-Provides-Financial-Guidance-for-2015-01-12-2015/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2015/01/News-Release-01-12-2015-1690223091247976.pdf)\n\nJanuary 8, 2015 \n\n[Revance Therapeutics Announces Publication of Positive Results From RT002 Phase 1/2 Study](/investors/Press-Releases/news-details/2015/Revance-Therapeutics-Announces-Publication-of-Positive-Results-From-RT002-Phase-12-Study-01-08-2015/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2015/Revance-Therapeutics-Announces-Publication-of-Positive-Results-From-RT002-Phase-12-Study-01-08-2015/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2015/01/News-Release-01-08-2015-1690223091247509.pdf)\n\nJanuary 5, 2015 \n\n[Revance Therapeutics Announces Initiation of BELMONT Phase 2 Active Comparator Trial of Injectable RT002](/investors/Press-Releases/news-details/2015/Revance-Therapeutics-Announces-Initiation-of-BELMONT-Phase-2-Active-Comparator-Trial-of-Injectable-RT002-01-05-2015/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2015/Revance-Therapeutics-Announces-Initiation-of-BELMONT-Phase-2-Active-Comparator-Trial-of-Injectable-RT002-01-05-2015/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2015/01/News-Release-01-05-2015-1690223091247121.pdf)\n\nDecember 18, 2014 \n\n[Revance Therapeutics Added to NASDAQ Biotechnology Index](/investors/Press-Releases/news-details/2014/Revance-Therapeutics-Added-to-NASDAQ-Biotechnology-Index-12-18-2014/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2014/Revance-Therapeutics-Added-to-NASDAQ-Biotechnology-Index-12-18-2014/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2014/12/News-Release-12-18-2014-1690223091247739.pdf)\n\nNovember 20, 2014 \n\n[Revance Therapeutics, Inc. Announces Participation in 26th Annual Piper Jaffray Healthcare Conference](/investors/Press-Releases/news-details/2014/Revance-Therapeutics-Inc.-Announces-Participation-in-26th-Annual-Piper-Jaffray-Healthcare-Conference-11-20-2014/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2014/Revance-Therapeutics-Inc.-Announces-Participation-in-26th-Annual-Piper-Jaffray-Healthcare-Conference-11-20-2014/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2014/11/News-Release-11-20-2014-1690223091247271.pdf)\n\nNovember 12, 2014 \n\n[Revance Therapeutics Releases Third Quarter 2014 Results](/investors/Press-Releases/news-details/2014/Revance-Therapeutics-Releases-Third-Quarter-2014-Results-11-12-2014/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2014/Revance-Therapeutics-Releases-Third-Quarter-2014-Results-11-12-2014/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2014/11/News-Release-11-12-2014-16902230912474.pdf)\n\nNovember 4, 2014 \n\n[Revance Therapeutics, Inc. Announces Participation in Credit Suisse 2014 Healthcare Conference](/investors/Press-Releases/news-details/2014/Revance-Therapeutics-Inc.-Announces-Participation-in-Credit-Suisse-2014-Healthcare-Conference-11-04-2014/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2014/Revance-Therapeutics-Inc.-Announces-Participation-in-Credit-Suisse-2014-Healthcare-Conference-11-04-2014/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2014/11/News-Release-11-04-2014-169022309124728.pdf)\n\nOctober 29, 2014 \n\n[Revance Therapeutics to Release Third Quarter 2014 Financial Results and Host Conference Call on Wednesday, November 12, 2014](/investors/Press-Releases/news-details/2014/Revance-Therapeutics-to-Release-Third-Quarter-2014-Financial-Results-and-Host-Conference-Call-on-Wednesday-November-12-2014-10-29-2014/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2014/Revance-Therapeutics-to-Release-Third-Quarter-2014-Financial-Results-and-Host-Conference-Call-on-Wednesday-November-12-2014-10-29-2014/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2014/10/News-Release-10-29-2014-169022309124773.pdf)\n\nOctober 1, 2014 \n\n[Revance Therapeutics Provides Update on RT001 Clinical Program for the Lead Indication for Crow's Feet Lines](/investors/Press-Releases/news-details/2014/Revance-Therapeutics-Provides-Update-on-RT001-Clinical-Program-for-the-Lead-Indication-for-Crows-Feet-Lines-10-01-2014/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2014/Revance-Therapeutics-Provides-Update-on-RT001-Clinical-Program-for-the-Lead-Indication-for-Crows-Feet-Lines-10-01-2014/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2014/10/News-Release-10-01-2014-1690223091247913.pdf)\n\nSeptember 22, 2014 \n\n[Revance Therapeutics Announces the Appointment of Azita Nejad as Vice President of Quality](/investors/Press-Releases/news-details/2014/Revance-Therapeutics-Announces-the-Appointment-of-Azita-Nejad-as-Vice-President-of-Quality-09-22-2014/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2014/Revance-Therapeutics-Announces-the-Appointment-of-Azita-Nejad-as-Vice-President-of-Quality-09-22-2014/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2014/09/News-Release-09-22-2014-1690223091247957.pdf)\n\nSeptember 2, 2014 \n\n[Revance Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)](/investors/Press-Releases/news-details/2014/Revance-Therapeutics-Announces-Inducement-Grants-Under-NASDAQ-Listing-Rule-5635c4-09-02-2014/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2014/Revance-Therapeutics-Announces-Inducement-Grants-Under-NASDAQ-Listing-Rule-5635c4-09-02-2014/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2014/09/News-Release-09-02-2014-1690223098036373.pdf)\n\nAugust 12, 2014 \n\n[Revance Therapeutics Appoints Industry Veteran Arthur P. Bertolino, M.D., Ph.D., M.B.A. as Chief Medical Officer](/investors/Press-Releases/news-details/2014/Revance-Therapeutics-Appoints-Industry-Veteran-Arthur-P.-Bertolino-M.D.-Ph.D.-M.B.A.-as-Chief-Medical-Officer-08-12-2014/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2014/Revance-Therapeutics-Appoints-Industry-Veteran-Arthur-P.-Bertolino-M.D.-Ph.D.-M.B.A.-as-Chief-Medical-Officer-08-12-2014/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2014/08/News-Release-08-12-2014-1690223098036915.pdf)\n\nAugust 12, 2014 \n\n[Revance Therapeutics Releases Second Quarter 2014 Financial Results](/investors/Press-Releases/news-details/2014/Revance-Therapeutics-Releases-Second-Quarter-2014-Financial-Results-08-12-2014/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2014/Revance-Therapeutics-Releases-Second-Quarter-2014-Financial-Results-08-12-2014/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2014/08/News-Release-08-12-2014-1690223098036437.pdf)\n\nJuly 29, 2014 \n\n[Revance Therapeutics to Release Second Quarter 2014 Financial Results and Host Conference Call on Tuesday, August 12, 2014](/investors/Press-Releases/news-details/2014/Revance-Therapeutics-to-Release-Second-Quarter-2014-Financial-Results-and-Host-Conference-Call-on-Tuesday-August-12-2014-07-29-2014/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2014/Revance-Therapeutics-to-Release-Second-Quarter-2014-Financial-Results-and-Host-Conference-Call-on-Tuesday-August-12-2014-07-29-2014/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2014/07/News-Release-07-29-2014-1690223098036632.pdf)\n\nJune 24, 2014 \n\n[Revance Therapeutics Announces Closing of Its Follow-on Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares](/investors/Press-Releases/news-details/2014/Revance-Therapeutics-Announces-Closing-of-Its-Follow-on-Public-Offering-and-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares-06-24-2014/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2014/Revance-Therapeutics-Announces-Closing-of-Its-Follow-on-Public-Offering-and-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares-06-24-2014/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2014/06/News-Release-06-24-2014-1690223098036367.pdf)\n\nJune 18, 2014 \n\n[Revance Therapeutics Announces Pricing of Its Public Offering of Common Stock](/investors/Press-Releases/news-details/2014/Revance-Therapeutics-Announces-Pricing-of-Its-Public-Offering-of-Common-Stock-06-18-2014/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2014/Revance-Therapeutics-Announces-Pricing-of-Its-Public-Offering-of-Common-Stock-06-18-2014/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2014/06/News-Release-06-18-2014-1690223098036722.pdf)\n\nJune 16, 2014 \n\n[Revance Therapeutics Announces Proposed Public Offering of Common Stock](/investors/Press-Releases/news-details/2014/Revance-Therapeutics-Announces-Proposed-Public-Offering-of-Common-Stock-06-16-2014/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2014/Revance-Therapeutics-Announces-Proposed-Public-Offering-of-Common-Stock-06-16-2014/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2014/06/News-Release-06-16-2014-1690223098036120.pdf)\n\nMay 21, 2014 \n\n[Revance Therapeutics Clinical Data to be Presented in \"Emerging Technologies\" Panel at the International Symposium of Facial Plastic Surgery in New York City](/investors/Press-Releases/news-details/2014/Revance-Therapeutics-Clinical-Data-to-be-Presented-in-Emerging-Technologies-Panel-at-the-International-Symposium-of-Facial-Plastic-Surgery-in-New-York-City-05-21-2014/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2014/Revance-Therapeutics-Clinical-Data-to-be-Presented-in-Emerging-Technologies-Panel-at-the-International-Symposium-of-Facial-Plastic-Surgery-in-New-York-City-05-21-2014/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2014/05/News-Release-05-21-2014-1690223098037252.pdf)\n\nMay 21, 2014 \n\n[Revance Therapeutics, Inc. Announces Participation in Jefferies 2014 Global Healthcare Conference](/investors/Press-Releases/news-details/2014/Revance-Therapeutics-Inc.-Announces-Participation-in-Jefferies-2014-Global-Healthcare-Conference-05-21-2014/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2014/Revance-Therapeutics-Inc.-Announces-Participation-in-Jefferies-2014-Global-Healthcare-Conference-05-21-2014/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2014/05/News-Release-05-21-2014-1690223098037700.pdf)\n\nMay 13, 2014 \n\n[Revance Therapeutics Releases First Quarter 2014 Financial Results](/investors/Press-Releases/news-details/2014/Revance-Therapeutics-Releases-First-Quarter-2014-Financial-Results-05-13-2014/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2014/Revance-Therapeutics-Releases-First-Quarter-2014-Financial-Results-05-13-2014/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2014/05/News-Release-05-13-2014-1690223098037689.pdf)\n\nMay 12, 2014 \n\n[Revance Appoints Mark A. Prygocki to Its Board of Directors](/investors/Press-Releases/news-details/2014/Revance-Appoints-Mark-A.-Prygocki-to-Its-Board-of-Directors-05-12-2014/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2014/Revance-Appoints-Mark-A.-Prygocki-to-Its-Board-of-Directors-05-12-2014/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2014/05/News-Release-05-12-2014-1690223104728879.pdf)\n\nApril 29, 2014 \n\n[Revance Therapeutics to Release First Quarter 2014 Financial Results and Host Conference Call on Tuesday, May 13, 2014](/investors/Press-Releases/news-details/2014/Revance-Therapeutics-to-Release-First-Quarter-2014-Financial-Results-and-Host-Conference-Call-on-Tuesday-May-13-2014-04-29-2014/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2014/Revance-Therapeutics-to-Release-First-Quarter-2014-Financial-Results-and-Host-Conference-Call-on-Tuesday-May-13-2014-04-29-2014/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2014/04/News-Release-04-29-2014-16902231047284.pdf)\n\nApril 21, 2014 \n\n[Revance Therapeutics Announces Positive Results From the RT002 Phase 1/2 Study in Glabellar Frown Lines](/investors/Press-Releases/news-details/2014/Revance-Therapeutics-Announces-Positive-Results-From-the-RT002-Phase-12-Study-in-Glabellar-Frown-Lines-04-21-2014/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2014/Revance-Therapeutics-Announces-Positive-Results-From-the-RT002-Phase-12-Study-in-Glabellar-Frown-Lines-04-21-2014/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2014/04/News-Release-04-21-2014-1690223104728674.pdf)\n\nMarch 31, 2014 \n\n[Revance Therapeutics Added to Russell 2000(R) and 3000(R) Indexes](/investors/Press-Releases/news-details/2014/Revance-Therapeutics-Added-to-Russell-2000R-and-3000R-Indexes-03-31-2014/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2014/Revance-Therapeutics-Added-to-Russell-2000R-and-3000R-Indexes-03-31-2014/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2014/03/News-Release-03-31-2014-1690223104728927.pdf)\n\nMarch 26, 2014 \n\n[Revance Therapeutics Releases Fourth Quarter and Full Year 2013 Financial Results and Provides 2014 Outlook](/investors/Press-Releases/news-details/2014/Revance-Therapeutics-Releases-Fourth-Quarter-and-Full-Year-2013-Financial-Results-and-Provides-2014-Outlook-03-26-2014/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2014/Revance-Therapeutics-Releases-Fourth-Quarter-and-Full-Year-2013-Financial-Results-and-Provides-2014-Outlook-03-26-2014/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2014/03/News-Release-03-26-2014-1690223104728861.pdf)\n\nMarch 12, 2014 \n\n[Revance Therapeutics to Release Fourth Quarter and Full Year 2013 Financial Results and Host Conference Call on Wednesday, March 26, 2014](/investors/Press-Releases/news-details/2014/Revance-Therapeutics-to-Release-Fourth-Quarter-and-Full-Year-2013-Financial-Results-and-Host-Conference-Call-on-Wednesday-March-26-2014-03-12-2014/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2014/Revance-Therapeutics-to-Release-Fourth-Quarter-and-Full-Year-2013-Financial-Results-and-Host-Conference-Call-on-Wednesday-March-26-2014-03-12-2014/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2014/03/News-Release-03-12-2014-1690223104729219.pdf)\n\nMarch 5, 2014 \n\n[Revance to Add Angus C. Russell as Chairman to Its Board of Directors](/investors/Press-Releases/news-details/2014/Revance-to-Add-Angus-C.-Russell-as-Chairman-to-Its-Board-of-Directors-03-05-2014/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2014/Revance-to-Add-Angus-C.-Russell-as-Chairman-to-Its-Board-of-Directors-03-05-2014/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2014/03/News-Release-03-05-2014-1690223104729135.pdf)\n\nFebruary 19, 2014 \n\n[Revance Therapeutics, Inc. Announces Participation in Cowen 34th Annual Health Care Conference](/investors/Press-Releases/news-details/2014/Revance-Therapeutics-Inc.-Announces-Participation-in-Cowen-34th-Annual-Health-Care-Conference-02-19-2014/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2014/Revance-Therapeutics-Inc.-Announces-Participation-in-Cowen-34th-Annual-Health-Care-Conference-02-19-2014/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2014/02/News-Release-02-19-2014-1690223104729478.pdf)\n\nFebruary 11, 2014 \n\n[Revance Therapeutics, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Over-Allotment Option](/investors/Press-Releases/news-details/2014/Revance-Therapeutics-Inc.-Announces-Closing-of-Initial-Public-Offering-and-Full-Exercise-of-Underwriters-Over-Allotment-Option-02-11-2014/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2014/Revance-Therapeutics-Inc.-Announces-Closing-of-Initial-Public-Offering-and-Full-Exercise-of-Underwriters-Over-Allotment-Option-02-11-2014/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2014/02/News-Release-02-11-2014-1690223104729152.pdf)\n\nFebruary 5, 2014 \n\n[Revance Therapeutics Announces Pricing of Initial Public Offering](/investors/Press-Releases/news-details/2014/Revance-Therapeutics-Announces-Pricing-of-Initial-Public-Offering-02-05-2014/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2014/Revance-Therapeutics-Announces-Pricing-of-Initial-Public-Offering-02-05-2014/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2014/02/News-Release-02-05-2014-16902231047292.pdf)\n\nApril 2, 2013 \n\n[Revance Therapeutics Announces $33 Million Series E Financing](/investors/Press-Releases/news-details/2013/Revance-Therapeutics-Announces-33-Million-Series-E-Financing-04-02-2013/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2013/Revance-Therapeutics-Announces-33-Million-Series-E-Financing-04-02-2013/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2013/04/News-Release-04-02-2013-1690223111337227.pdf)\n\nMarch 25, 2013 \n\n[Revance Therapeutics Announces Appointment of Lauren Silvernail as Chief Financial Officer](/investors/Press-Releases/news-details/2013/Revance-Therapeutics-Announces-Appointment-of-Lauren-Silvernail-as-Chief-Financial-Officer-03-25-2013/default.aspx)\n\n[Read More](/investors/Press-Releases/news-details/2013/Revance-Therapeutics-Announces-Appointment-of-Lauren-Silvernail-as-Chief-Financial-Officer-03-25-2013/default.aspx)\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_news/2013/03/News-Release-03-25-2013-1690223111337273.pdf)\n\n✓\n\nThanks for sharing!\n\n[AddToAny](https://www.addtoany.com \"Share Buttons\")\n\n[More…](#addtoany \"Show all\")\n"
        }
      ]
    },
    {
      "section_name": "Financial Reports",
      "links": [
        {
          "title": "Quarterly Results Q1 2024",
          "url": "https://investors.revance.com/investors/financials/quarterly-results/default.aspx",
          "content": "[Skip to main content](#maincontent)\n\n[![Revance Logo](//s202.q4cdn.com/113424049/files/design/logo-revance.png)](/)\n\n  * [COMPANY](https://www.revance.com)\n  * [PRODUCTS AND PIPELINE](https://www.revance.com/products)\n  * [INVESTORS](/)\n\n[INVESTOR RELATIONS](/)[PRESS RELEASES](/investors/Press-Releases)[EVENTS + PRESENTATIONS](/investors/events-and-presentations/events)[FINANCIALS & FILINGS](/investors/financials)[CORPORATE GOVERNANCE](/investors/corporate-governance/governance-documents)\n\n[STOCK INFORMATION](/investors/stock-info)[ANALYST COVERAGE](/investors/analyst-coverage)[INVESTOR FAQS](/investors/investor-faqs)[CONTACT US](/investors/contact-us)\n\n![Investors](//s202.q4cdn.com/113424049/files/design/irmenubanner.png)\n\n  * [CAREERS](https://www.revance.com/careers/)\n  * [IN THE NEWS](https://www.revance.com/news)\n  * [CONTACT US](https://www.revance.com/company/contact-us/)\n\n\n\nUser Menu\n\n  * [LOGIN](https://hcp.revanceready.com/s/login/)\n\n\n\n# Quarterly Results\n\nIR MENU\n\nLoading financial reports...\n"
        },
        {
          "title": "Annual Report 2023",
          "url": "https://investors.revance.com/investors/financials/annual-reports/default.aspx",
          "content": "[Skip to main content](#maincontent)\n\n[![Revance Logo](//s202.q4cdn.com/113424049/files/design/logo-revance.png)](/)\n\n  * [COMPANY](https://www.revance.com)\n  * [PRODUCTS AND PIPELINE](https://www.revance.com/products)\n  * [INVESTORS](/)\n\n[INVESTOR RELATIONS](/)[PRESS RELEASES](/investors/Press-Releases)[EVENTS + PRESENTATIONS](/investors/events-and-presentations/events)[FINANCIALS & FILINGS](/investors/financials)[CORPORATE GOVERNANCE](/investors/corporate-governance/governance-documents)\n\n[STOCK INFORMATION](/investors/stock-info)[ANALYST COVERAGE](/investors/analyst-coverage)[INVESTOR FAQS](/investors/investor-faqs)[CONTACT US](/investors/contact-us)\n\n![Investors](//s202.q4cdn.com/113424049/files/design/irmenubanner.png)\n\n  * [CAREERS](https://www.revance.com/careers/)\n  * [IN THE NEWS](https://www.revance.com/news)\n  * [CONTACT US](https://www.revance.com/company/contact-us/)\n\n\n\nUser Menu\n\n  * [LOGIN](https://hcp.revanceready.com/s/login/)\n\n\n\n# Annual Reports and Proxies\n\nIR MENU\n\nSelecting the value will change the page content\n\n## Forms 10-K\n\nDate | View  \n---|---  \nFebruary 28, 2024| \n\n  * [pdf 10-K dated February 28, 2024 in pdf format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/fdc51f74-a336-4099-b6e0-3a3e7ebfe7a1.pdf)\n  * [excel 10-K dated February 28, 2024 in excel format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/d6b3409c-650d-4099-8958-ec159ff5b050.xls)\n  * [zip 10-K dated February 28, 2024 in zip format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/6cb8c78f-30a1-4a6d-b380-d5b9aeda783a.zip)\n  * [html 10-K dated February 28, 2024 in html format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/ad244ac2-4ee0-40cc-a129-0f0784015cda.html)\n\n  \nFebruary 28, 2023| \n\n  * [pdf 10-K dated February 28, 2023 in pdf format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/e77c9901-a67a-4d25-a8de-0267cdc88604.pdf)\n  * [excel 10-K dated February 28, 2023 in excel format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/e16f2de8-8345-4417-98de-af9c4aa8b36f.xls)\n  * [zip 10-K dated February 28, 2023 in zip format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/4b47e12c-75c1-4415-abbf-b9bd6731f46e.zip)\n  * [html 10-K dated February 28, 2023 in html format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/d102466d-e605-4ca4-a39f-efd7b04013af.html)\n\n  \nFebruary 28, 2022| \n\n  * [pdf 10-K dated February 28, 2022 in pdf format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/65217919-893f-4cbc-808d-ae93b00fb38d.pdf)\n  * [excel 10-K dated February 28, 2022 in excel format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/9feb172d-3361-4cc1-bb9b-969bebbd59d2.xls)\n  * [zip 10-K dated February 28, 2022 in zip format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/1604ce86-892c-4b9f-8c70-de054e13e977.zip)\n  * [html 10-K dated February 28, 2022 in html format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/8aed3570-3e1b-42f4-aab8-bc8cba0cb262.html)\n\n  \nFebruary 25, 2021| \n\n  * [pdf 10-K dated February 25, 2021 in pdf format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/bb5eba0b-1d77-4e66-9602-fc7da948f675.pdf)\n  * [excel 10-K dated February 25, 2021 in excel format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/9265fbd4-9851-4d82-b034-b948088a3a98.xls)\n  * [zip 10-K dated February 25, 2021 in zip format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/9dd64986-d446-4ec0-9a47-7f0efdcb3053.zip)\n  * [html 10-K dated February 25, 2021 in html format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/9fb02680-7a2d-4ea4-bcc0-437364033ee1.html)\n\n  \nFebruary 26, 2020| \n\n  * [pdf 10-K dated February 26, 2020 in pdf format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/e89ec0b4-a405-4864-9e72-01605ebb4769.pdf)\n  * [excel 10-K dated February 26, 2020 in excel format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/8c00bbc0-be7c-45ec-839e-979e10b9a447.xls)\n  * [zip 10-K dated February 26, 2020 in zip format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/8ace3aa1-12db-4860-bdb5-9c81578853b1.zip)\n  * [html 10-K dated February 26, 2020 in html format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/ed5904a0-c05d-4f30-904a-1be68dd00646.html)\n\n  \nFebruary 28, 2019| \n\n  * [pdf 10-K dated February 28, 2019 in pdf format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/d1c330de-dbfb-4b15-9f48-293235295250.pdf)\n  * [excel 10-K dated February 28, 2019 in excel format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/78a410e2-5abf-4388-8d4d-99baf406774a.xls)\n  * [zip 10-K dated February 28, 2019 in zip format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/00ef7ea3-5b6e-4ba2-af99-727c8b7d2235.zip)\n  * [html 10-K dated February 28, 2019 in html format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/0575d838-2b28-4fa9-9bee-31c467498618.html)\n\n  \nMarch 02, 2018| \n\n  * [pdf 10-K dated March 02, 2018 in pdf format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/64ec30c2-4c70-4d25-8f2c-2ac4d5769fef.pdf)\n  * [excel 10-K dated March 02, 2018 in excel format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/cb0ad2f1-189a-45e7-8ab4-2d52ea279dce.xls)\n  * [zip 10-K dated March 02, 2018 in zip format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/ffec73ee-bac6-4e4c-a0a8-321f3cdbb268.zip)\n  * [html 10-K dated March 02, 2018 in html format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/a67a241a-1374-4a2c-9e35-28b9e23ab6c6.html)\n\n  \nFebruary 28, 2017| \n\n  * [pdf 10-K dated February 28, 2017 in pdf format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/1e21799d-df11-4c48-a968-f0555433336d.pdf)\n  * [excel 10-K dated February 28, 2017 in excel format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/9979a34a-db17-41d0-96b3-a2e936fa09b3.xls)\n  * [zip 10-K dated February 28, 2017 in zip format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/0cc92d26-fa0e-4e9f-abdc-6baae8603224.zip)\n  * [html 10-K dated February 28, 2017 in html format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/73e6fc29-b4c9-46bc-b907-3f8079711802.html)\n\n  \nMarch 04, 2016| \n\n  * [pdf 10-K dated March 04, 2016 in pdf format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/9326e8f5-319a-4c89-ade6-d558f20acd44.pdf)\n  * [excel 10-K dated March 04, 2016 in excel format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/744c98a0-1376-4649-a32f-7af33da03522.xls)\n  * [zip 10-K dated March 04, 2016 in zip format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/daf45cc3-b4ce-4f60-a4e6-e909a1c01de1.zip)\n  * [html 10-K dated March 04, 2016 in html format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/3e534b7a-fe15-47e8-9bed-abb22afdb252.html)\n\n  \nMarch 04, 2015| \n\n  * [pdf 10-K dated March 04, 2015 in pdf format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/fefffbe8-9edf-4ad7-8623-7d1cab214e17.pdf)\n  * [excel 10-K dated March 04, 2015 in excel format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/4bab5979-9449-4817-b9f9-0e5a7699d904.xls)\n  * [zip 10-K dated March 04, 2015 in zip format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/c456bd99-3fc2-4731-a520-0cba229c169e.zip)\n  * [html 10-K dated March 04, 2015 in html format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/8964de61-0230-4817-98b4-41abc606b7b8.html)\n\n  \nMarch 28, 2014| \n\n  * [pdf 10-K dated March 28, 2014 in pdf format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/1e82e130-7b51-47a8-aa1a-0c0394622519.pdf)\n  * [excel 10-K dated March 28, 2014 in excel format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/dd288ebc-ed47-42a4-8120-329a0854512a.xls)\n\n  \n  \nSelecting the value will change the page content\n\n## Proxy Statements\n\nDate | View  \n---|---  \nMarch 21, 2024| \n\n  * [pdfDEFA14A dated March 21, 2024 in pdf format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/8ced1553-e977-4c1e-894f-93d975398b06.pdf)\n\n  \nMarch 21, 2024| \n\n  * [pdfDEF 14A dated March 21, 2024 in pdf format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/9cd812b9-5b84-4176-be52-9d6a31985957.pdf)\n  * [excelDEF 14A dated March 21, 2024 in excel format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/6fd405f0-eb7c-4705-8005-691c89e0d2a0.xls)\n  * [zipDEF 14A dated March 21, 2024 in zip format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/e23a72dd-3c70-4aaa-b19e-3f2b93d34f3a.zip)\n  * [htmlDEF 14A dated March 21, 2024 in html format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/aea8462b-f00c-4828-b243-4d470bbfc6a1.html)\n\n  \nMarch 31, 2023| \n\n  * [pdfDEFA14A dated March 31, 2023 in pdf format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/72980a43-b70c-4675-a5a1-682635a86151.pdf)\n\n  \nMarch 23, 2023| \n\n  * [pdfDEF 14A dated March 23, 2023 in pdf format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/d4106872-57e7-46bd-9ff2-0c0bae1bf334.pdf)\n  * [excelDEF 14A dated March 23, 2023 in excel format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/95d7b74f-a552-47d6-9113-344730d33e6c.xls)\n  * [zipDEF 14A dated March 23, 2023 in zip format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/32061a25-8807-4864-82db-0b1e191dafac.zip)\n  * [htmlDEF 14A dated March 23, 2023 in html format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/457166c4-a91d-4c3f-b35d-0c8f0716c4c5.html)\n\n  \nMarch 23, 2023| \n\n  * [pdfDEFA14A dated March 23, 2023 in pdf format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/1158adac-6e7c-45c5-a462-720b19276417.pdf)\n\n  \nMarch 24, 2022| \n\n  * [pdfDEF 14A dated March 24, 2022 in pdf format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/bcb86351-75fb-4d10-ae19-da2785ebf6fb.pdf)\n  * [excelDEF 14A dated March 24, 2022 in excel format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/e09e5def-fb6b-49d7-95ba-b8d2b9770032.xls)\n\n  \nMarch 24, 2022| \n\n  * [pdfDEFA14A dated March 24, 2022 in pdf format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/e9f1bfb6-da06-4a51-884a-f40926af4187.pdf)\n\n  \nMarch 24, 2021| \n\n  * [pdfDEF 14A dated March 24, 2021 in pdf format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/b304126c-5bf2-4083-b1e0-df58b2606239.pdf)\n  * [excelDEF 14A dated March 24, 2021 in excel format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/15309634-a4a7-40e9-8208-2e8969d2b06f.xls)\n\n  \nMarch 24, 2021| \n\n  * [pdfDEFA14A dated March 24, 2021 in pdf format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/f150541d-d519-4512-914e-06d057ec9796.pdf)\n\n  \nMarch 12, 2021| \n\n  * [pdfPRE 14A dated March 12, 2021 in pdf format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/bd5c5ef1-70f2-4941-8c96-33b7d158c5ea.pdf)\n  * [excelPRE 14A dated March 12, 2021 in excel format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/4062502a-345f-4685-81e4-7b3ab6704c95.xls)\n\n  \nMarch 11, 2021| \n\n  * [pdfDEF 14A dated March 11, 2021 in pdf format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/889a79be-8f85-4287-a434-86736b9cf028.pdf)\n  * [excelDEF 14A dated March 11, 2021 in excel format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/a827deef-190e-447e-93e1-f8d7a60d1ace.xls)\n\n  \nMarch 26, 2020| \n\n  * [pdfDEF 14A dated March 26, 2020 in pdf format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/288d6186-f0c8-42b6-adee-c87c6425b246.pdf)\n  * [excelDEF 14A dated March 26, 2020 in excel format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/502e135b-8884-4cb0-afee-65de4b3928cc.xls)\n\n  \nMarch 26, 2020| \n\n  * [pdfDEFA14A dated March 26, 2020 in pdf format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/58e900d2-c32e-4f5f-b99e-8baadb5ac497.pdf)\n\n  \nMarch 25, 2019| \n\n  * [pdfDEF 14A dated March 25, 2019 in pdf format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/927cdf1c-18ac-4a26-a64f-5f82a880bebc.pdf)\n  * [excelDEF 14A dated March 25, 2019 in excel format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/b67bb3b9-5d4a-44e2-bc5f-7deffc3e961c.xls)\n\n  \nMarch 20, 2018| \n\n  * [pdfDEF 14A dated March 20, 2018 in pdf format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/50072e55-5ee3-438b-b650-4119283b1692.pdf)\n  * [excelDEF 14A dated March 20, 2018 in excel format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/a936814b-4d31-47b3-a501-779c804c83f0.xls)\n\n  \nMarch 24, 2017| \n\n  * [pdfDEF 14A dated March 24, 2017 in pdf format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/d22987a2-780c-46ce-bed5-ca5caa274392.pdf)\n  * [excelDEF 14A dated March 24, 2017 in excel format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/885f18aa-c681-4570-bf4c-a7d1c1189bb8.xls)\n\n  \nMarch 18, 2016| \n\n  * [pdfDEF 14A dated March 18, 2016 in pdf format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/f4060a7c-7c0a-4bc6-b150-aaa5aa5ad7f5.pdf)\n  * [excelDEF 14A dated March 18, 2016 in excel format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/ddf8ea56-f7ec-48e4-b724-f88e1ac8e788.xls)\n\n  \nMarch 26, 2015| \n\n  * [pdfDEF 14A dated March 26, 2015 in pdf format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/db8d7aaa-c4b3-4d69-ae06-5147a9cf1d1c.pdf)\n  * [excelDEF 14A dated March 26, 2015 in excel format download](//d18rn0p25nwr6d.cloudfront.net/CIK-0001479290/ad3a1ae1-9d07-4bac-8a9f-53b9b3bd4bba.xls)\n\n  \n  \n✓\n\nThanks for sharing!\n\n[AddToAny](https://www.addtoany.com \"Share Buttons\")\n\n[More…](#addtoany \"Show all\")\n"
        }
      ]
    },
    {
      "section_name": "Events & Presentations",
      "links": [
        {
          "title": "Upcoming Events 2024",
          "url": "https://investors.revance.com/investors/events-and-presentations/events/default.aspx",
          "content": "[Skip to main content](#maincontent)\n\n[![Revance Logo](//s202.q4cdn.com/113424049/files/design/logo-revance.png)](/)\n\n  * [COMPANY](https://www.revance.com)\n  * [PRODUCTS AND PIPELINE](https://www.revance.com/products)\n  * [INVESTORS](/)\n\n[INVESTOR RELATIONS](/)[PRESS RELEASES](/investors/Press-Releases)[EVENTS + PRESENTATIONS](/investors/events-and-presentations/events)[FINANCIALS & FILINGS](/investors/financials)[CORPORATE GOVERNANCE](/investors/corporate-governance/governance-documents)\n\n[STOCK INFORMATION](/investors/stock-info)[ANALYST COVERAGE](/investors/analyst-coverage)[INVESTOR FAQS](/investors/investor-faqs)[CONTACT US](/investors/contact-us)\n\n![Investors](//s202.q4cdn.com/113424049/files/design/irmenubanner.png)\n\n  * [CAREERS](https://www.revance.com/careers/)\n  * [IN THE NEWS](https://www.revance.com/news)\n  * [CONTACT US](https://www.revance.com/company/contact-us/)\n\n\n\nUser Menu\n\n  * [LOGIN](https://hcp.revanceready.com/s/login/)\n\n\n\n# Events + Presentations\n\nIR MENU\n\n##  Upcoming Events\n\n##  Presentation\n\nJanuary 8, 2024\n\n2024 JP Morgan Healthcare Conference\n\n[ Download (opens in new window) ](https://s202.q4cdn.com/113424049/files/doc_presentation/2024/01/JPM-Presentation_Draft_0107_FINAL2.pdf)\n\n[View All](https://investors.revance.com/investors/events-and-presentations/presentations/default.aspx)\n\n##  Archived Events\n\n[View All Events](https://investors.revance.com/investors/events-and-presentations/Archived-Events/default.aspx)\n\n✓\n\nThanks for sharing!\n\n[AddToAny](https://www.addtoany.com \"Share Buttons\")\n\n[More…](#addtoany \"Show all\")\n"
        }
      ]
    }
  ]
}